DEF 14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:


☐		Preliminary Proxy Statement

☐		Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒		Definitive Proxy Statement

☐		Definitive Additional Materials

☐		Soliciting Material under §240.14a-12

TRANSMEDICS GROUP, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement if other than Registrant)

Payment of Filing Fee (Check all boxes that apply):



☒		No fee required

☐		Fee paid previously with preliminary materials

☐		Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

TRANSMEDICS GROUP, INC.

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS

TO BE HELD MAY 25, 2023

We are pleased to notify you that we will hold the 2023 annual meeting of our shareholders on May 25, 2023, at 8:00 a.m. Eastern Time. The annual meeting of shareholders will be held in a virtual format at www.virtualshareholdermeeting.com/TMDX2023 for the following purposes:

To elect eight (8) directors, each to serve until the 2024 annual meeting of our shareholders;

To approve, on a non-binding advisory basis, the compensation paid to our named executive officers;

To approve an amendment to the TransMedics Group, Inc. 2019 Stock Incentive Plan (the “2019 Plan”) to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2019 Plan by 1,000,000 shares;

To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023; and

To transact such other business as may properly come before the meeting or any adjournments and postponements thereof.

Our board of directors has established the close of business on March 31, 2023 as the “record date” for this annual meeting. This means that you are entitled to vote at this meeting (by remote communication or by proxy) if our stock records show that you owned our common stock at that time.

Our 2023 annual meeting will be a virtual meeting, which means it will be conducted via live webcast. We believe hosting a virtual meeting will allow for greater shareholder attendance at the annual meeting by enabling shareholders who might not otherwise be able to travel to a physical meeting to attend online and participate from any location. If you attend online, you can vote your shares and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/TMDX2023. Details regarding how to attend the meeting online are more fully described in the Notice (as defined below) and this proxy statement.

Under Securities and Exchange Commission rules that allow companies to furnish proxy materials to shareholders over the Internet, we have elected to make our proxy materials available to all of our shareholders over the Internet. We will be able to provide shareholders with the information they need, while at the same time conserving natural resources and lowering the cost of delivery. On or about April 12, 2023, we will commence sending to our shareholders a Notice of Internet Availability of Proxy Materials (the “Notice”), containing instructions on how to access our proxy statement for our 2023 annual meeting of shareholders and our 2022 annual report to shareholders. The Notice also provides instructions on how to vote online or vote by phone and includes instructions on how to receive a paper copy of the proxy materials by mail.

Whether you plan to attend the annual meeting or not, it is important that you cast your vote by remote communication at the meeting or by proxy. You may vote over the Internet, telephone or by mail. You are urged to vote in accordance with the instructions set forth in this proxy statement. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting, whether or not you can attend. You will need the 16-digit control number included with the Notice, on your proxy card, or the instructions that accompany your proxy materials to attend our 2023 annual meeting.

-2-

Thank you for your continued support of TransMedics Group, Inc. We look forward to seeing you at the annual meeting.

TRANSMEDICS GROUP, INC.

Stephen Gordon

Chief Financial Officer, Treasurer and Secretary

April 12, 2023

Andover, Massachusetts

-3-

TABLE OF CONTENTS


PROXY STATEMENT			5
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS			5
INFORMATION ABOUT THE MEETING AND VOTING			5
PROPOSAL 1 ELECTION OF DIRECTORS			11
PROPOSAL 2 ADVISORY VOTE ON EXECUTIVE COMPENSATION			22
PROPOSAL 3 AMENDMENT TO THE TRANSMEDICS GROUP, INC. 2019 STOCK INCENTIVE PLAN			23
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT			31
EXECUTIVE COMPENSATION			33
REPORT OF THE AUDIT COMMITTEE			55
CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS			56
EXECUTIVE OFFICERS			57
PROPOSAL 4 RATIFICATION OF THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM			59
DELINQUENT SECTION 16(A) REPORTS			61
SHAREHOLDER PROPOSALS FOR 2024 ANNUAL MEETING			61
ANNUAL REPORT			61
HOUSEHOLDING OF PROXY MATERIALS			61
APPENDIX A			63

-4-

PROXY STATEMENT

ANNUAL MEETING OF SHAREHOLDERS OF

TRANSMEDICS GROUP, INC.

TO BE HELD MAY 25, 2023

INTRODUCTION

The board of directors of TransMedics Group, Inc. (our “Board”), is soliciting proxies from shareholders for its use at the 2023 annual meeting of shareholders, and at any adjournment or adjournments of that meeting. The annual meeting is scheduled to be held on May 25, 2023, at 8:00 a.m., Eastern Time, at www.virtualshareholdermeeting.com/TMDX2023.

This proxy statement relates to the solicitation of proxies by our Board for use at the annual meeting.

On or about April 12, 2023, we will commence sending the Notice of Internet Availability of Proxy Materials (the “Notice”) to all shareholders entitled to vote at the annual meeting.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS

This proxy statement and our 2022 Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which includes our audited financial statements, are available for viewing, printing and downloading at http://investors.transmedics.com/ under the Investors/Financial Information page. Additionally, you can find a copy of our Annual Report on Form 10-K on the website of the Securities and Exchange Commission at www.sec.gov. You may also obtain a printed copy of our Annual Report on Form 10-K, including our financial statements, free of charge, from us by following the instructions included on the Notice or by sending a written request to: TransMedics Group, Inc., 200 Minuteman Road, Andover, MA 01810, Attention: Corporate Secretary.

INFORMATION ABOUT THE MEETING AND VOTING

Purposes of the Meeting

The purposes of the annual meeting are:

To elect eight (8) directors, each to serve until the 2024 annual meeting of our shareholders;

To approve, on a non-binding advisory basis, the compensation paid to our named executive officers;

To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023; and

To transact such other business as may properly come before the meeting or any adjournments and postponements thereof.

Shareholders Entitled to Vote at the Meeting

Our Board has established the close of business on March 31, 2023 as the “record date” for this annual meeting. This means that you are entitled to vote at this meeting (and any adjournments) if our records show that you

-5-

owned our common stock at that time. As of this record date, 32,534,003 shares of our common stock, including 24,315 shares of restricted stock, were issued and outstanding, held by approximately 41 registered shareholders of record. Each issued and outstanding share of common stock as of the record date is entitled to one vote on each matter properly to come before the annual meeting and can be voted only if the record owner of that share, determined as of the record date, is present by remote communication at the meeting or represented by proxy. A list of shareholders entitled to vote will be available for examination during the annual meeting at www.virtualshareholdermeeting.com/TMDX2023.

Voting Shares That You Hold In Your Name

If you are a shareholder of record on the record date for the annual meeting, you may vote by proxy or you may attend the annual meeting and vote by remote communication at the meeting. If you do not attend the annual meeting, you may:

•

VOTE BY INTERNET — www.proxyvote.com. Use the Internet to transmit your voting instructions up until 11:59 p.m., Eastern Time, on May 24, 2023. Have the Notice in hand when you access the website. Follow the steps outlined on the secured website.

•

VOTE BY MAIL — If you requested and received a proxy card by mail, mark, sign and date your proxy card and return it in the postage-paid envelope we will provide or mail it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

•

VOTE BY PHONE — Use a touch tone phone by calling the toll-free number 1-800-690-6903 to transmit your voting instructions up until 11:59 p.m., Eastern Time, on May 24, 2023. Have the Notice in hand when you access the phone number. Follow the steps outlined on the phone line.

Virtual Meeting

Our 2023 annual meeting will be a virtual meeting, which will be conducted via live webcast. We believe hosting a virtual meeting will allow for greater shareholder attendance at the annual meeting by enabling shareholders who might not otherwise be able to travel to our physical meeting to attend online and participate from any location.

To participate in the annual meeting virtually via the Internet, please visit www.virtualshareholdermeeting.com/TMDX2023. You will need the 16-digit control number included on your Notice, your proxy card or the instructions that accompanied your proxy materials.

Instructions should also be provided on the voting instruction card provided by your bank or brokerage firm. If you do not have your 16-digit control number and choose to attend the meeting online, you will be able to listen to the meeting only, however, and you will not be able to vote or submit questions during the meeting.

Attending the Annual Meeting

The 2023 annual meeting will be held entirely online at www.virtualshareholdermeeting.com/TMDX2023. A summary of the information you need to attend the 2023 annual meeting online is provided below:

•

Instructions on how to attend and participate via the Internet, including how to demonstrate proof of common stock ownership, are posted at www.virtualshareholdermeeting.com/TMDX2023.

•

Questions regarding how to attend and participate via the Internet will be answered by calling 1-800-690-6903 on the day before the annual meeting and the day of the 2023 annual meeting.

•

Please have your 16-digit control number to enter the 2023 annual meeting.

•

Shareholders may submit questions while attending the 2023 annual meeting via the Internet.

-6-

•

The meeting webcast will begin promptly at 8:00 a.m., Eastern Time.

•

We encourage you to access the meeting prior to the start time. Online check-in will begin at 7:30 a.m., Eastern Time, and you should allow ample time for the check-in procedures.

Webcast replay of the annual meeting will be available until the sooner of May 25, 2024 or the date of the next annual meeting of shareholders to be held in 2024.

Technical Assistance for the Virtual Access to the Annual Meeting

We will have technicians ready to assist you with any technical difficulties you may have accessing the annual meeting website. If you encounter any difficulties accessing the annual meeting website during the check-in or meeting time, please call the technical support number that will be posted on the annual meeting login page.

Voting Shares That You Hold in Brokerage or Similar Accounts

Many shareholders hold their shares through a broker, bank or other nominee rather than directly in their own name. If you hold your shares in one of these ways, you are considered a beneficial owner, not a record owner, and you therefore have no direct vote on any matter to come before the annual meeting. Your broker, bank or nominee will send you voting instructions for you to use in directing the broker, bank or nominee in how to vote your shares. Your broker, bank or nominee may allow you to deliver your voting instructions via the telephone or the Internet.

A “broker non-vote” occurs when a broker, bank or other nominee holding shares for a beneficial owner does not vote the shares on a proposal because the broker, bank or other nominee does not have discretionary voting power for a particular item and has not received instructions from the beneficial owner regarding voting. Brokers, banks or other nominees who hold shares for the accounts of their clients have discretionary authority to vote shares if specific instructions are not given with respect to routine matters. Although the determination of whether a broker, bank or other nominee will have discretionary voting power for a particular item is typically determined only after proxy materials are filed with the SEC, we expect that the proposal on ratification of the appointment of our independent registered public accounting firm (Proposal 4) will be a routine matter and that the election of each nominee for director (Proposal 1), the proposal on an advisory vote on executive compensation (Proposal 2), and the proposal on the vote to amend the 2019 Plan (Proposal 3) will be non-routine matters. Accordingly, if you hold your shares through a broker, bank or other nominee and you do not timely provide your broker, bank or other nominee with specific instructions on how to vote your shares, your broker, bank or other nominee would not be authorized to cast a vote on your behalf on Proposal 1 (election of each nominee for director), Proposal 2 (advisory vote on executive compensation) or Proposal 3 (amendment to the 2019 Plan), but would be authorized to cast a vote on your behalf, in its discretion, on Proposal 4 (ratification of the appointment of PricewaterhouseCoopers LLP). In such cases, a “broker non-vote” may be entered with respect to your shares on Proposal 1, Proposal 2, and Proposal 3 to reflect that your broker was present with respect to your shares at the meeting but was not exercising voting rights on your behalf with respect to those shares. Broker non-votes and abstentions will have no effect on the outcome of each proposal. Brokers, banks and other nominees generally have discretionary authority to vote on the ratification of the appointment of an independent registered public accounting firm (Proposal 4); thus, we do not expect any broker non-votes on this matter.

Your Voting Options on Each of the Proposals

You may vote “for”, “against” or “abstain” with respect to the election of each nominee for director (Proposal 1).

You may vote “for,” “against” or “abstain” with respect to the proposal on the compensation of our executive officers (Proposal 2).

-7-

You may vote “for,” “against” or “abstain” with respect to the proposal on the amendment to the 2019 Plan (Proposal 3).

You may vote “for,” “against” or “abstain” with respect to the proposal on the ratification of the appointment of PricewaterhouseCoopers LLP (Proposal 4).

If any other matter is presented at the annual meeting, your proxy provides that your shares will be voted by the proxy holder named in the proxy card in accordance with his or her best judgment. At the time this proxy statement was first made available, we knew of no matters that needed to be acted on at the annual meeting, other than those discussed in this proxy statement.

Our Board’s Voting Recommendations

Our Board recommends that you vote:

•

FOR the election as director of each of the eight (8) individuals named as its nominees in this proxy statement (Proposal 1);

•

FOR the approval, on a non-binding advisory basis, of the compensation paid to our named executive officers (Proposal 2);

•

FOR the approval of the amendment to the 2019 Plan (Proposal 3); and

•

FOR the ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023 (Proposal 4).

If any other matter is properly brought before the annual meeting, the Company — through the individual named in the proxy and acting as the “proxy holder,” or his or her designee, and pursuant to the blanket authorization granted under the proxy — will vote your shares on that matter in accordance with the discretion and judgment of the proxy holder.

It is very important that your shares be represented and voted whether or not you plan to attend the annual meeting. The Company may be negatively impacted if it does not receive the required votes FOR proposal 3, as it will limit the Company’s ability to (i) execute corporate and other business plans and (ii) use equity as an incentive for its employees and other service providers.

Required Votes to Approve Each Proposal

As a shareholder, you are entitled to cast one vote per share for each of the eight (8) nominees for election as directors at the annual meeting, but you may not cumulate your votes (in other words, you may not cast votes representing eight times the number of your shares entitled to vote in favor of a single nominee). A majority of the votes properly cast for election of a director will effect such election. However, in the event that shareholders are to select among several alternative nominees in an election of directors (such as when there are more nominees than directorships), directors will be elected from among the nominees based on those directors receiving the most “for” votes until all board seats are filled. A properly returned proxy indicating “abstain” with respect to the election of one or more directors will not be counted as a vote cast with respect to the director or directors indicated. “Broker non-votes” will not be counted as votes cast on the proposal and will have no effect on the election of directors.

A majority of the votes properly cast at the meeting will approve: (i) the proposal to amend the 2019 Plan, (ii) the proposal to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023; and (iii) all other matters that arise at the annual meeting.

-8-

Please note, however, that because the vote on the ratification of PricewaterhouseCoopers LLP is advisory in nature, the results of such vote will not be binding upon our Board or its committees.

No vote is required for approval of the compensation of our named executive officers, as this is an advisory vote. Our Board and its committees value the opinions of our shareholders and will consider the result of this vote in making future decisions relating to executive compensation arrangements.

Quorum

Massachusetts law provides that any shareholder action at a meeting requires that a quorum exist with respect to that meeting. Once a share is represented for any purpose at a meeting, it is deemed by Massachusetts law to be present for quorum purposes for the remainder of the meeting and (unless the shareholder attends solely to object to lack of notice, defective notice or the conduct of the meeting on other grounds, or a new record date is or must be set for any such adjournment) any adjournment of that meeting.

A majority of the shares of common stock entitled to vote at the annual meeting, present by remote communication at the meeting or by proxy, will constitute a quorum for all purposes at the meeting. If a quorum should not be present, the annual meeting may be adjourned from time to time until a quorum is obtained.

Shares held of record by shareholders who (by remote communication at the meeting or by proxy) abstain from voting on any or all proposals (and shares represented by “broker non-votes,” described above under “Voting Shares That You Hold in Brokerage or Similar Accounts”) will be included in the number of shares present at the meeting for purposes of determining the presence of a quorum. However, abstentions and “broker non-votes” as to any proposal will not be considered to be votes that have been “cast” on that proposal and therefore will not affect the outcome of the vote on any proposals described by this proxy statement.

Voting on Possible Other Matters

We are not aware that any person intends to propose that any matter, other than the four numbered proposals specifically described by this proxy statement, be presented for consideration or action by our shareholders at our annual meeting. If any such other matter should properly come before the meeting, however, favorable action on such matter would generally require the votes cast favoring the matter exceeding the votes opposing the matter to constitute favorable action on the matter, unless our restated articles of organization or bylaws or applicable law require otherwise. If you vote by proxy, you will be granting the proxy holder authority to vote your shares on any such other matter in accordance with his discretion and judgment.

Revocation of Proxies or Voting Instructions

A shareholder of record who has delivered a proxy card in response to this solicitation may revoke it before it is exercised at the annual meeting by executing and delivering a timely and valid later-dated proxy, by a timely and valid later Internet or telephone vote, by voting by remote communication at the meeting or by giving written notice to the Secretary. Attendance at the meeting online will not have the effect of revoking a proxy unless a shareholder gives proper written notice of revocation to the Secretary before the proxy is exercised or the shareholder votes by remote communication at the meeting. Beneficial owners who have directed their broker, bank or nominee as to how to vote their shares should contact their broker, bank or nominee for instructions as to how they may revoke or change those voting directions.

-9-

Solicitation of Proxies

Our Board is making this solicitation of proxies for our annual meeting. We will bear all costs of such solicitation, including the cost of preparing and distributing this proxy statement and the enclosed form of proxy and including the cost of hosting the virtual meeting. After the initial distribution of this proxy statement, proxies may be solicited by mail, telephone, or personally by directors, officers, employees or agents of the Company. Brokerage houses and other custodians, nominees and fiduciaries will be requested to forward soliciting materials to beneficial owners of shares held by them for the accounts of beneficial owners, and we will pay their reasonable out-of-pocket expenses.

-10-

PROPOSAL 1

ELECTION OF DIRECTORS

Our Board currently consists of eight (8) directors. In accordance with the terms of our restated articles of organization and amended and restated bylaws, all of our directors serve for one-year terms and are elected annually. We are nominating the eight (8) current directors listed below for re-election. If re-elected, each of these eight (8) nominees will serve on our Board until the 2024 annual meeting, or until his or her successor is duly elected and qualified in accordance with our restated articles of organization and amended and restated bylaws, or his or her earlier death, resignation or removal.

Below is certain information concerning our Board’s nominees for election at this year’s annual meeting. The biographies of each of the nominees below contain information regarding the experiences, qualifications, attributes or skills that caused the nominating and corporate governance committee and our Board to determine that the person should be re-elected as a director of the Company.

Following the director biographies is information concerning our corporate governance structure, including descriptions of the standing committees of our Board, namely our audit, compensation and nominating and corporate governance committees. The directors serving on each committee are listed in the descriptions below. Our directors may also serve on other committees of our Board and the board of directors of the Company’s subsidiaries that are not required to be described by this proxy statement and which are therefore not identified in the information below.

Elsewhere in this proxy statement you will find information concerning the number of shares of our common stock that are beneficially owned by each of our directors (see “Security Ownership of Certain Beneficial Owners and Management”) and information regarding the compensation of our directors (see “Non-Employee Director Compensation”). We urge you to review all of this information when deciding how to vote on Proposal 1.

Our Board recommends that you vote FOR all eight (8) of the nominees named below.

The following persons have been nominated for election to our Board:


Name	Year First Elected as Director	Position
Waleed Hassanein, M.D.	1998	President and Chief Executive Officer; Director
James R. Tobin	2011	Director; Chair of the Board; Chair of the Compensation Committee
Edward M. Basile	2016	Director; Chair of the Nominating and Corporate Governance Committee
Thomas J. Gunderson	2016	Director
Edwin M. Kania, Jr.	2003	Director
Stephanie Lovell	2021	Director
Merilee Raines	2020	Director; Chair of the Audit Committee
David Weill, M.D.	2019	Director

Waleed Hassanein, M.D., age 54, our founder, has served as our President and Chief Executive Officer and as a member of our Board since August 1998. Prior to founding TransMedics, Inc. Dr. Hassanein completed a three-year cardiac surgery research fellowship at West Roxbury VA Medical Center and Brigham and Women’s Hospital, a Harvard Medical School affiliate. Prior to his research fellowship, Dr. Hassanein completed two years of general surgery residency at Georgetown University Medical Center. Dr. Hassanein earned his M.D. degree from Georgetown University in 1993. Prior to transferring to Georgetown University, Dr. Hassanein attended Cairo University School of Medicine from 1985 to 1989, and holds a General Certificate of Education from the University of London. We believe that Dr. Hassanein is qualified to serve on our board of directors because of his extensive experience in the medical field and his extensive knowledge of our company based on his role as founder and President and Chief Executive Officer.

-11-

James R. Tobin, age 78, has served as Chairman of our Board since 2011. Mr. Tobin is the retired President and CEO of Boston Scientific Corporation, a medical device company, where he served from 1999 to 2009. Prior to Boston Scientific, Mr. Tobin was the President and CEO of Biogen Inc., and, from 1994 to 1997, its President and Chief Operating Officer. Before Biogen, Mr. Tobin spent 22 years with Baxter International Inc., rising from Financial Analyst to President and Chief Operating Officer. Mr. Tobin currently serves as a director of Globus Medical Inc., a public company, and Xenter, Inc. and Impulse Dynamics, each of which is a private company. Mr. Tobin has also served on the boards of Oxford Immunotec, Inc., from 2014 to 2021, Corindus Vascular Robotics, from 2018 to 2019, Curis, Inc., from 1995 to 2015, Medical Simulation Corp, from 2012 to 2018, CardioDX, Inc., from 2014 to 2017, Chiasma, Inc., from 2015 to 2016, and Aptus Endosystems, Inc. from 2011 to 2015. Mr. Tobin holds an AB from Harvard College and an MBA from Harvard Business School. Mr. Tobin also served to Lieutenant in the U.S. Navy. We believe Mr. Tobin is qualified to serve on our board of directors because of his decades of experience as President and Chief Executive Officer or Chief Operating Officer of three large biotechnology and medical device companies.

Edward M. Basile, age 75, has served as a member of our Board since February 2016. He is currently retired. During his 25-year tenure with the law firm King & Spalding, Mr. Basile served as Chair of the firm’s FDA and Life Sciences Practice and on the firm’s Policy and Compensation Committees. Mr. Basile’s law practice included representing large, medium and small medical device, pharmaceutical, and biotechnology companies before the U.S. Food and Drug Administration. Mr. Basile also served in the Chief Counsel’s Office of FDA as Associate Chief Counsel for Drugs & Biologics and Associate Chief Counsel for Enforcement from 1975 to 1985. Mr. Basile received a BSME from Lafayette College and a JD from George Washington University Law School. We believe Mr. Basile’s decades of experience representing medical device, pharmaceutical and biotechnology companies qualify him to serve on our board of directors.

Thomas J. Gunderson, age 72, has served as a member of our Board since August 2016. Mr. Gunderson has served as Chair of the Board of Directors at the Minneapolis Heart Institute Foundation from 2015 to 2020, as Executive in Residence at the University of Minnesota’s Medical Industry Leadership Institute from 2016 to present, as a member of the Board of Directors of Merit Medical Systems, Inc. from 2017 to present, as a member of American Heart Association Science and Technology Accelerator Committee from 2015 to 2017 and as managing director and senior research analyst at Piper Jaffray (with a focus on medical technology companies) from 1992 to 2016. We believe Mr. Gunderson is qualified to serve on our board of directors because of his more than 25 years of substantive experience in the medical device industry, his seasoned perspective on the challenges, trends and opportunities of publicly-traded medical device manufacturers, and understanding of our competitive position within its industry, as well as his strong background in financial and economic analysis and valuable insights regarding business development and acquisition opportunities.

Edwin M. Kania, Jr., age 66, has served as a member of our board of directors since 2003. Mr. Kania is the managing partner of FarField Partners, a personal venture capital investment and advisory firm. Previously, Mr. Kania was co-founder of Flagship Pioneering and served as the firm’s initial chairman between 2001 and 2014 and as a managing partner through 2020. He is presently a partner emeritus. He was also managing partner of the predecessor OneLiberty Funds that were an early lead investor in our company. During Mr. Kania’s 40 years in the venture capital industry, he has served on the boards of numerous privately and publicly held companies. Mr. Kania earned his Bachelor’s degree in physics from Dartmouth College and his MBA from Harvard Business School. We believe that Mr. Kania’s significant experience investing in and then serving as a board member of numerous life science companies, including several that have emerged as significant revenue businesses, make him qualified to serve on our board of directors.

Stephanie Lovell, age 63, has served as a member of our Board of Directors since March 2021. Ms. Lovell served as the executive vice president, Medicare and chief legal officer for Blue Cross Blue Shield of Massachusetts, Inc. (“BCBSMA”) from July 2015 to December 2021. Ms. Lovell previously served as the senior vice president and general counsel of BCBSMA from December 2011 to July 2015. Prior to BCBSMA, Ms. Lovell was the senior vice president of administration and general counsel for Boston Medical Center from March 2007 to

-12-

December 2011. She also previously served as the first assistant attorney general in the Massachusetts Office of the Attorney General and as the executive director for the Massachusetts State Ethics Commission. Ms. Lovell currently serves as a director of Cyclerion Therapeutics, Inc. and serves as a member of its audit committee and compensation committee. Ms. Lovell also serves as a director of Accompany Health, a private company. Ms. Lovell previously served as a director of the New England Law Foundation and The Partnership Inc. and as a trustee of the Massachusetts Taxpayers Foundation, each until her resignation in 2021. She also is a member of the investment committee of Goodwill Industries of Massachusetts. Ms. Lovell received a Bachelor’s degree in philosophy from Hamilton College and a J.D. from Boston University School of Law. We believe Ms. Lovell’s experience in the healthcare payer and reimbursement markets, as well as government and regulatory affairs qualifies her to serve as a member of our board of directors.

Merilee Raines, age 67, has served as a member of our Board of Directors since January 2021. Ms. Raines served as Chief Financial Officer of IDEXX Laboratories, Inc. from October 2003 until her retirement in May 2013. Prior to becoming Chief Financial Officer, Ms. Raines held several management positions with IDEXX Laboratories, including Corporate Vice President of Finance, Vice President and Treasurer of Finance, Director of Finance, and Controller. IDEXX Laboratories develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing industries. Ms. Raines has served on the board of directors of Watts Water Technology since 2011, and serves on its audit committee and nominating and corporate governance committee. Ms. Raines has served on the board of directors of Ocular Therapeutics, Inc. since September 2021 and serves on its audit committee. Ms. Raines previously served on the board of directors of Benchmark Electronics, Inc., from May 2018 until June 2021. Ms. Raines also served as a member of the Board of Directors of Affymetrix, Inc., from January 2015 until it was acquired in March 2016. Ms. Raines also served as a member of the Board of Directors of Aratana Therapeutics, Inc., from February 2014 until it was acquired in July 2019. Ms. Raines has also served on the boards of directors of several private companies, including Excelitas Technologies Corporation since 2018, Dead River Company from 2018 until 2021 and PetVet Care Centers LLC from 2016 until 2018. Ms. Raines holds a Bachelor’s degree in mathematics from Bowdoin College and an MBA from the University of Chicago. We believe that Ms. Raines’ extensive financial expertise and experience as an executive and director of public companies qualify her to serve as a member of our board of directors.

David Weill, M.D., age 59, has served as a member of our Board since 2019 and has served since 2016 as Principal of the Weill Consulting Group, a biomedical consulting group focusing on organ transplantation and lung disease. Dr. Weill has been involved in the transplant and advanced lung disease fields for over 20 years, directing clinical programs and providing care to those afflicted with significant lung diseases. Dr. Weill served as Director of the Lung and Heart-Lung Transplant Program at Stanford University Medical Center from 2005 until 2016 and is the former Director of the Stanford Center for Advanced Lung Diseases. Dr. Weill received his Bachelor of Arts from Tulane University and his M.D. degree from Tulane University Medical School. He completed his Internship and Residency in Internal Medicine at Parkland Hospital, University of Texas Southwestern and his Fellowship in Pulmonary and Critical Care Medicine and Lung Transplantation at the University of Colorado at Denver and Health Sciences Center. We believe Dr. Weill’s experience at a major medical research institute and his expertise in organ transplantation and pulmonary disease qualify him to serve as a member of our board of directors.

Board Leadership Structure

Our Board is currently led by its Chairman, Mr. Tobin. Our Board recognizes that it is important to determine an optimal board leadership structure to ensure the independent oversight of management as the Company continues to grow. We separate the roles of Chief Executive Officer and Chairman of the board in recognition of the differences between the two roles. The Chief Executive Officer is responsible for setting the strategic direction for the Company and the day-to-day leadership and performance of the Company, while the Chairman provides guidance to the Chief Executive Officer and presides over meetings of the full Board. We believe this separation of responsibilities provides a balanced approach to managing our Board and overseeing the Company.

-13-

Our Board has concluded that our current leadership structure is appropriate at this time. However, our Board will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate.

Director Independence

Our Board currently consists of eight (8) members. Our Board has determined that seven (7) of those members, Mr. Tobin, Mr. Basile, Mr. Gunderson, Mr. Kania, Ms. Lovell, Ms. Raines and Dr. Weill, are independent directors in accordance with the listing requirements of the Nasdaq Stock Market (“Nasdaq”). Under the rules of Nasdaq, independent directors must comprise a majority of a listed company’s board of directors. In addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company’s audit and compensation committees be independent and that director nominees be selected or recommended for the board’s selection by independent directors constituting a majority of the independent directors or by a nominating and corporate governance committee comprised solely of independent directors. Under the rules of Nasdaq, a director will only qualify as “independent” if, in the opinion of that company’s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that such person is “independent” as defined by the applicable rules of Nasdaq and the Exchange Act.

Audit committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Exchange Act. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1) accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries or (2) be an affiliated person of the listed company or any of its subsidiaries.

Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that each of our directors, with the exception of Dr. Hassanein, is an “independent director” as defined under applicable rules of Nasdaq, including, in the case of all the members of our audit committee, the independence criteria set forth in Rule 10A-3 under the Exchange Act, and in the case of all the members of our compensation committee, the independence criteria set forth in Rule 10C-1 under the Exchange Act. In making such determination, our board of directors considered the relationships that each such non-employee director has with our Company and all other facts and circumstances that our board of directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each non-employee director. Dr. Hassanein is not an independent director under these rules because he is our President and Chief Executive Officer.

Role of Board in Risk Oversight Process

Our Board has an active role, as a whole and also at the committee level, in overseeing the management of our risks. Our board of directors is responsible for general oversight of risks and regular review of information regarding our risks, including credit risks, liquidity risks and operational risks. The compensation committee is responsible for overseeing the management of risks associated with our compensation policies and practices. The audit committee is responsible for overseeing the management of risks relating to accounting matters and financial reporting. The nominating and corporate governance committee is responsible for overseeing the management of risks associated with potential conflicts of interest and significant issues of corporate social responsibility. Although each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board is regularly informed through discussions from committee members about such risks. Our Board believes its administration of its risk oversight function has not negatively affected our board of directors’ leadership structure.

-14-

Committees and Attendance

Our Board held four (4) meetings during 2022. During that time, no member of our Board attended fewer than 75% of the aggregate of (i) the total number of meetings of our Board (held during the period for which he or she was a director) and (ii) the total number of meetings held by all committees of our Board on which he or she served (held during the period that such director served).

In addition to regular meetings of our Board, the Company’s non-management directors meet in executive sessions without management participation.

Our Board has established three standing committees — audit, compensation and nominating and corporate governance — each of which operates under a charter that has been approved by our Board. The charters for each committee are available under the Investors/Corporate Governance page on our website at www.transmedics.com.

Audit Committee

The members of our audit committee are Mr. Basile, Mr. Gunderson, Mr. Kania and Ms. Raines. Ms. Raines currently chairs the audit committee. Our board of directors has determined that each member of the audit committee satisfies the independence standards for audit committee purposes as that term is defined by the applicable rules of Nasdaq and the Exchange Act, and that each has sufficient knowledge in financial and auditing matters to serve on the audit committee. Our Board has also determined that each of Mr. Kania, Ms. Raines and Mr. Gunderson is an “audit committee financial expert,” as defined under Item 407 of Regulation S-K.

The audit committee’s responsibilities include:

•

appointing, approving the compensation of, and evaluating the qualifications, performance and independence of our independent registered public accounting firm;

•

overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of reports from such firm, and pre-approving all audit and permitted non-audit services to be performed by our independent registered public accounting firm;

•

reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures, including earnings releases;

•

reviewing and discussing with management and our independent registered public accounting firm any material issues regarding accounting principles and financial statement presentations;

•

coordinating our board of directors’ oversight of our internal control over financial reporting, disclosure controls and procedures, code of business conduct and ethics, procedures for complaints and legal and regulatory matters;

•

discussing our risk management policies with management;

•

establishing policies regarding hiring employees from our independent registered public accounting firm and procedures for the receipt and retention of accounting related complaints and concerns;

•

meeting independently with our independent registered public accounting firm and management;

•

reviewing and approving any related person transactions;

•

overseeing our guidelines and policies governing risk assessment and risk management;

•

overseeing the integrity of our information technology systems, process and data;

•

preparing the audit committee report required by Securities and Exchange Commission (“SEC”) rules;

•

reviewing and assessing, at least annually, the adequacy of the audit committee’s charter; and

•

performing, at least annually, an evaluation of the performance of the audit committee.

-15-

All audit services and all non-audit services, other than de minimis non-audit services, to be provided to us by our independent registered public accounting firm must be approved in advance by our audit committee.

During the fiscal year ended December 31, 2022, the audit committee met five (5) times. The report of the audit committee is included in this proxy statement under “Report of the Audit Committee.”

Compensation Committee

The members of our compensation committee are Mr. Gunderson, Ms. Raines, Mr. Tobin and Dr. Weill. Mr. Tobin chairs the compensation committee. Our Board has determined that each member of the compensation committee satisfies the independence standards of the applicable rules of the Nasdaq Stock Market and Rule 10C-1 of the Exchange Act and are “non-employee directors” as defined in Section 16b-3 of the Exchange Act. The compensation committee may delegate any of the responsibilities of the full committee to subcommittees and may delegate such responsibilities of the full committee to executive officers of the Company and other persons as may be permitted by applicable laws, rules or regulations and in accordance with the listing standards set forth by Nasdaq.

Our compensation committee’s responsibilities include:

•

assisting our board of directors in developing and reviewing potential candidates for executive positions;

•

reviewing our overall compensation strategy, including base salary, incentive compensation and equity-based grants;

•

reviewing and approving corporate goals and objectives relevant to the compensation of our chief executive officer and our other executive officers;

•

recommending to our board of directors the compensation of our chief executive officer and other executive officers;

•

reviewing and making recommendations to the board of directors with respect to director compensation;

•

overseeing and administering our cash and equity incentive plans;

•

reviewing, considering and selecting, to the extent determined to be advisable, a peer group of appropriate companies for purposing of benchmarking and analysis of compensation for our executive officers and directors;

•

reviewing and approving all employment contracts and other compensation, severance and change-in- control arrangements for our executive officers;

•

recommending to our board of directors any stock ownership guidelines for our executive officers and non-employee directors;

•

retaining, appointing or obtaining advice of a compensation consultant, legal counsel or other advisor, and determining the compensation and independence of such consultant or advisor;

•

preparing, if required, the compensation committee report on executive compensation for inclusion in our annual proxy statement in accordance with the proxy rules;

•

monitoring our compliance with the requirements of Sarbanes-Oxley relating to loans to directors and officers;

•

overseeing our compliance with applicable SEC rules regarding shareholder approval of certain executive compensation matters;

•

reviewing the risks associated with our compensation policies and practices;

-16-

•

reviewing and assessing, at least annually, the adequacy of the compensation committee’s charter; and

•

performing, on an annual basis, an evaluation of the performance of the compensation committee.

During the fiscal year ended December 31, 2022, the compensation committee met six (6) times.

Compensation Consultant

The compensation committee previously engaged Radford, a business unit of Aon plc (“Radford”), as its independent compensation consultant. In September 2022, the compensation committee engaged Pearl Meyer & Partners, LLC (“Pearl Meyer”) as its independent compensation consultant.

As the compensation committee’s independent compensation consultant, Radford provided, and Pearl Meyer provides, analysis and recommendations to the compensation committee regarding:

•

trends and emerging topics with respect to executive compensation;

•

peer group selection for executive compensation comparisons;

•

compensation programs for executives, directors, and our employees generally; and

•

stock utilization and related metrics.

When requested, Radford consultants attended, and Pearl Meyer consultants attend, meetings of the compensation committee, including executive sessions in which executive compensation-related matters are discussed without the presence of management. Both Radford and Pearl Meyer at all times reported to the compensation committee and not to management, although Radford and Pearl Meyer met with management for purposes of gathering information for its analyses and recommendations.

In determining to engage Radford and Pearl Meyer, the compensation committee considered the independence of Radford and Pearl Meyer, taking into consideration relevant factors, including the absence of other services provided to the Company by Radford or Pearl Meyer, as applicable, the amount of fees the Company paid to Radford or Pearl Meyer, as applicable, as a percentage of their total revenue, the policies and procedures of Radford and Pearl Meyer that are designed to prevent conflicts of interest, any business or personal relationship of the individual compensation advisors employed by Radford or Pearl Meyer with any executive officer of the Company, any business or personal relationship the individual compensation advisors employed by Radford or Pearl Meyer have with any member of the compensation committee, and any stock of the Company owned by Radford or Pearl Meyer or the individual compensation advisors employed by them. The compensation committee has determined, based on its analysis and in light of all relevant factors, including the factors listed above, that the work of Radford and Pearl Meyer and the individual compensation advisors employed by them as compensation consultants to the compensation committee has not created any conflicts of interest, and that Radford is independent pursuant to the independence standards set forth in the Nasdaq listing standards promulgated pursuant to Section 10C of the Exchange Act.

The compensation committee will assess Pearl Meyer’s independence and potential conflicts of interest on a regular basis.

Nominating and Corporate Governance Committee

The members of our nominating and corporate governance committee are Mr. Basile, Ms. Lovell, Mr. Tobin and Dr. Weill. Mr. Basile chairs the nominating and corporate governance committee. Our board of directors has determined that each member of the nominating and corporate governance committee satisfies the independence standards of the applicable rules of the Nasdaq Stock Market.

-17-

Our nominating and corporate governance committee’s responsibilities include:

•

identifying individuals qualified to become members of our board of directors consistent with criteria approved by the board and receiving nominations for such qualified individuals;

•

recommending to our board of directors the persons to be nominated for election as directors and to each committee of the board;

•

establishing a policy under which our shareholders may recommend a candidate to the nominating and corporate governance committee for consideration for nomination as a director;

•

reviewing and recommending committee slates on an annual basis;

•

recommending to our board of directors qualified candidates to fill vacancies on our board of directors;

•

developing and recommending to our board of directors a set of corporate governance principals applicable to us and reviewing the principles on at least an annual basis;

•

reviewing and making recommendations to our board with respect to our board leadership structure and board committee structure;

•

reviewing, in concert with our board of directors, our policies and practices with respect to significant issues of corporate social responsibility (including diversity and inclusion and community involvement) and environmental sustainability and periodically review the Company’s public disclosures with respect to such matters;

•

making recommendations to our board of directors processes for annual evaluations of the performance of our board of directors, our chief executive officer and committees of our board of directors;

•

overseeing the process for annual evaluations of our board of directors, chief executive officer and committees of our board of directors and certifying that performance of our chief executive officer and other members of executive management is being properly evaluated;

•

considering and reporting to our board of directors any questions of possible conflicts of interest of members of our board of directors;

•

providing new director orientation and continuing education for existing directors on a periodic basis;

•

overseeing the maintenance and presentation to our board of directors of management’s plans for succession to senior management positions in the Company;

•

reviewing and assessing, at least annually, the adequacy of the nominating and corporate governance committee’s charter; and

•

performing, on an annual basis, an evaluation of the performance of the nominating and corporate governance committee.

During the fiscal year ended December 31, 2022, the nominating and corporate governance committee met three (3) times.

Global Code of Business Conduct and Ethics

We have adopted a written global code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Our global code of business conduct and ethics is available under the Investors/Corporate Governance page of our website, www.transmedics.com. In addition, we will post on our website all other disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the code and policy.

Our corporate governance guidelines are available under the Investors/Corporate Governance page of our website, www.transmedics.com.

-18-

Director Nomination Process and Board Diversity

In considering whether to recommend any particular candidate for inclusion in our Board’s slate of recommended director nominees, our nominating and corporate governance committee takes into account each candidate’s ability, judgment and experience and the overall diversity and composition of our Board. We also value experience on other public company boards of directors and board committees.

The biography for each of the director nominees included herein indicate each nominee’s experience, qualifications, attributes and skills that led our nominating and corporate governance committee and our Board to conclude each such director should continue to serve as a director of our Company. Our nominating and corporate governance committee and our Board believe that each of the nominees has the individual attributes and characteristics required of each of our directors, and the nominees as a group possess the skill sets and specific experience desired of our Board as a whole.

We look for a Board that represents diversity as to experience, gender, and ethnicity/race, and that reflects a range of talents, ages, skills, viewpoints, professional experiences, geographies, and educational backgrounds. Our nominating and corporate governance committee does not have a policy (formal or informal) with respect to diversity, but takes into consideration each candidate’s ability, judgment and experience and the overall diversity and composition of our Board when recommending director nominees. We value the many kinds of diversity reflected in our director nominees.

Board Diversity Matrix (as of April 12, 2023)


Total Number of Directors	8
Part I: Gender Identity	Female		Male		Non-Binary		Did Not Disclose Gender
Directors		2		6		—		—
Part II: Demographic Background
African American or Black		1		—		—		—
Alaskan Native or Native American		—		—		—		—
Asian		—		—		—		—
Hispanic or Latinx		—		—		—		—
Native Hawaiian or Pacific Islander		—		—		—		—
White		1		6		—		—
Two or More Races or Ethnicities		—		—		—		—
Part III:
LGBTQ+		1

Shareholders have the right under our amended and restated bylaws to directly nominate director candidates for election at an annual meeting of shareholders, without any action or recommendation on the part of the nominating and corporate governance committee or our Board, by submitting to the Company as to each nominee that the shareholder proposes for election or re-election as a director (i) all information relating to such nominee that would be required to be disclosed in solicitations of proxies for the election of such nominee as a director pursuant to Regulation 14A under the Exchange Act and such nominee’s written consent (I) to be named as a nominee in the Company’s proxy statement, proxy card, and/or ballot, if the Board approves such inclusion, and (II) to serve as a director if elected, and (ii) a description of all direct and indirect compensation, reimbursement, indemnification and other material arrangements, agreements or understandings during the past three years, and any other material relationship, if any, between or concerning such shareholder and any Shareholder Associated Person (as defined in the Company’s amended and restated bylaws), on the one hand, and the proposed nominee, and his or her respective affiliates or associates, on the other hand. Any such nomination must be made by a shareholder of record of the Company at the time of making such nomination and meet such other requirements

-19-

as are set forth in the Company’s amended and restated bylaws. Additionally, any shareholder that intends to solicit proxies in support of a director nominee other than our Board’s nominees also must comply with Rule 14a-19 under the Exchange Act. The nominating and corporate governance committee does not have a written policy regarding shareholder nominations, but the committee will consider candidates proposed by shareholders if made in accordance with our amended and restated bylaws. Such nomination information should be submitted to: TransMedics Group, Inc., 200 Minuteman Road, Suite 302, Andover, MA 01810, Attention: Corporate Secretary.

Communication with Directors

Any shareholder or other interested parties desiring to communicate with our Board, or one or more of our directors, may send a letter addressed to the board of directors, TransMedics Group, Inc., 200 Minuteman Road, Suite 302, Andover, MA 01810, Attention: Corporate Secretary. All such letters will be promptly forwarded to the appropriate members of our Board or individual directors, as applicable, by the Secretary. The mailing envelope should contain a clear notation that the enclosed letter is a “Shareholder-Board Communication” or “Shareholder-Director Communication.” All such letters should clearly state whether the intended recipients are all members of our Board or certain specified individual directors.

Director Attendance at Annual Meeting

While we do not have a formal policy regarding director attendance at the annual meeting of shareholders, we expect our Board members to prepare for, attend and participate in all Board and applicable committee meetings, including by means of remote communication. Each of our directors attended our 2022 annual meeting of shareholders.

Non-Employee Director Compensation

The following table presents the total compensation for each person who served as a non-employee member of our Board during 2022. Other than as set forth in the table and described more fully below, we did not pay any compensation to any of the other non-employee members of our Board. Dr. Hassanein, our President and Chief Executive Officer, receives no compensation for his services as a director and, as a result, is not included in the table below. The compensation received by Dr. Hassanein for his services as an employee in the fiscal year ended December 31, 2022 is described in the “Summary Compensation Table” and the accompanying narrative description.


Name	Fees earned or paid in cash ($) (1)		Option awards ($) (2)		All Other Compensation ($) (3)		Total ($)
James R. Tobin		95,000		213,461				308,461
Edward M. Basile		60,500		213,461		771		274,732
Thomas J. Gunderson		57,500		213,461		3,296		247,257
Edwin M. Kania, Jr.		50,000		213,461				263,461
Stephanie Lovell		45,000		213,461				258,461
Merilee Raines		67,500		213,461		539		281,499
David Weill, M.D.		52,500		213,461				265,961

(1)	The amounts reported in this column represent the aggregate cash compensation paid to each of our non-employee directors in respect of the fiscal year ended December 31, 2022.

(2)

The amounts reported in this column represent the aggregate grant date fair value of an option to purchase our common stock granted to each of our non-employee directors in the fiscal year ended December 31, 2022, computed in accordance with FASB ASC 718, excluding the effect of estimated forfeitures. The assumptions used to value this option for this purpose are set forth in Note 10 to our financial statements

-20-

filed with our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. These amounts do not represent the actual amounts paid to or realized by the director for these awards.

(3)	The amounts reported in this column represent travel expense reimbursements issued to certain of our non-employee directors.

As of December 31, 2022, our non-employee directors held options to purchase the number of shares of common stock set forth in the table below.


Name	Shares Subject to Outstanding Options
James R. Tobin		42,934
Edward M. Basile		62,219
Thomas J. Gunderson		62,219
Edwin M. Kania, Jr.		27,000
Stephanie Lovell		23,193
Merilee Raines		33,750
David Weill, M.D.		42,934

Non-Employee Director Compensation Policy

The following structure was used to compensate our non-employee directors in 2022:


	Board or Committee Chair		Board or Committee Member
Annual cash retainer	$	75,000	$	40,000
Additional annual cash retainer for Audit Committee	$	20,000	$	10,000
Additional annual cash retainer for Compensation Committee	$	15,000	$	7,500
Additional annual cash retainer for Nominating and Corporate Governance Committee	$	10,500	$	5,000
Annual equity award		13,500 Stock Options		13,500 Stock Options
Initial appointment equity retainer		20,500 Stock Options		20,500 Stock Options

Cash retainers are payable in arrears in four equal quarterly installments, provided that the amount of such payment is prorated for any portion of such quarter that the director was not serving on our Board or the relevant committee thereof. The committee chair cash retainers are provided in lieu of committee member cash retainers. Annual grants of stock options vest in full on the first anniversary of the grant date, and initial appointment stock options vest one-third (1/3) on the first anniversary of the grant date with the remaining portion vesting monthly over the following 24 months. Each such grant of stock options is generally subject to the non-employee director’s continued service through the vesting date, or, if earlier, upon the director’s death or disability or a change in control. All non-employee directors were granted an option to purchase 13,500 shares of common stock June 1, 2022.

-21-

PROPOSAL 2

ADVISORY VOTE ON EXECUTIVE COMPENSATION

We are seeking your vote, on a non-binding advisory basis, to approve the compensation of our named executive officers as described in the Compensation Discussion and Analysis, the compensation tables and related narrative disclosure contained in this proxy statement, which is commonly referred to as a “say on pay” vote. Because your “say on pay” vote is advisory, it will not be binding on the compensation committee or the Board. However, the compensation committee and the Board will review the “say on pay” voting results and take them into consideration when making future decisions regarding executive compensation.

The philosophy and principal objectives of our executive compensation programs are to attract, fairly compensate, appropriately incentivize, and retain superior executive talent in a manner that aligns their long-term interests with those of our shareholders. Our executive compensation program is designed to be:

•

Competitively Positioned: Target compensation should be competitive with that being offered to individuals in comparable roles at other companies with which we compete for talent to ensure that we attract and retain the best people to lead our success. Our Compensation Committee generally targets the median of the market for target compensation opportunities but can set compensation for executives above or below that level based on factors such as individual and Company performance, an executive’s role and responsibilities relative to executives in similar positions in the market, and an executive’s actual and potential impact on the successful execution of our strategy, among others.

•

Performance-Driven and Shareholder-Aligned: A meaningful portion of total compensation should be variable and linked to the achievement of specific short- and long-term performance objectives and designed to drive shareholder value creation.

•

Responsibly Governed: Decisions about compensation should be guided by best-practice governance standards and rigorous processes that encourage prudent decision-making.

Consistent with this philosophy, a significant portion of the total compensation opportunity for each of our executives is based on our performance.

Shareholders are urged to read the Compensation Discussion and Analysis section of this proxy statement, which discusses how our compensation program implements our compensation philosophy. The compensation committee and the Board of Directors believe that these policies and procedures are effective in implementing our compensation philosophy and in achieving the goals of our executive compensation program.

Required Vote of Shareholders

Although the “say on pay” vote we are asking you to cast is non-binding, the Board and compensation committee value the views of our shareholders and will consider the outcome of the vote when making future decisions regarding executive compensation. The affirmative vote of a majority of the votes cast by holders of shares of common stock who are present by remote communication or by proxy at a meeting at which a quorum is present is required (on a non-binding advisory basis) to approve the compensation of our named executive officers. We expect to hold an advisory “say on pay” vote to approve the compensation of our named executive officers annually until the next advisory vote on the frequency of such advisory votes, which will occur no later than our 2028 Annual Meeting of Shareholders.

Our Board recommends that you vote FOR the proposal to approve, on a non-binding advisory basis, the compensation paid to our named executive officers.

-22-

PROPOSAL 3

AMENDMENT TO THE TRANSMEDICS GROUP, INC. 2019 STOCK INCENTIVE PLAN

Our 2019 Plan was originally approved by our shareholders in 2019 in connection with our initial public offering. On April 18, 2022, our Board of Directors adopted the Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan (the “Amended Plan”), subject to shareholder approval, and on February 21, 2023, our Board of Directors ratified the Amended Plan, subject to shareholder approval. The Amended Plan amends our 2019 Plan to (i) increase the number of shares of our common stock available for issuance thereunder by 1,000,000 shares, (ii) prohibit the payment of dividend or dividend equivalents on a current basis with respect to unvested awards, (iii) extend the expiration date of the Amended Plan until June 1, 2033 and (iv) increase the annual limits on non-employee director compensation. The material terms and features of the Amended Plan are described under “Summary of the Amended Plan” below.

If shareholders do not approve this Proposal 3, the Amended Plan will not become effective and the 2019 Plan will remain in effect in accordance with its terms. If shareholders do approve this Proposal 3, the Amended Plan will become effective as of the date of such shareholder approval. We will continue to maintain our 2019 Employee Stock Purchase Plan and our Inducement Plan (the “Inducement Plan”), whether or not this Proposal 3 is approved.

REASONS TO VOTE FOR THIS PROPOSAL

Equity awards are an essential part of our compensation program

We believe that equity compensation has been, and will continue to be, an essential part of our compensation program. We view our employees as a key differentiator in the competitive marketplace in which we operate and believe that they are vital in driving our performance. We also believe that equity compensation is essential to successfully attract and retain talent.

Equity awards incentivize retention and increases in shareholder value

Our equity-based compensation program consists primarily of stock options and restricted stock units, as described in more detail in our Compensation Discussion and Analysis. Stock options provide value only if our stock price increases over time. We believe that equity awards have been and will continue to play an important role in incentivizing our employees and other service providers to drive increases in shareholder value.

The Amended Plan is consistent with principles of good corporate governance

Our Board believes that the Amended Plan will promote the interests of shareholders and is consistent with principles of good corporate governance, including:

•

No Evergreen Share Pool. The plan does not include an “evergreen” share pool that would increase the number of shares available without shareholder approval.

•

No Liberal Share Recycling. Shares used to satisfy tax withholding with respect to awards and the exercise price for stock options do not recycle back into the plan.

•

No Discounted Stock Options or Stock Appreciation Rights. All stock options and stock appreciation rights (“SAR”) under the plan must have an exercise or base value that is not less than the closing price of a share of our common stock on the date of grant (or, if no closing price is reported for that date, on the immediately preceding date on which a closing price was reported).

•

No Repricing. Other than in connection with certain corporate transactions affecting the Company, the plan prohibits any repricing of underwater stock options or SARs without shareholder approval.

•

No Automatic “Single-Trigger” Accelerated Vesting. The Amended Plan does not provide for automatic accelerated vesting of awards upon a change in control or other corporate transaction.

-23-

•

No Dividends or Dividend Equivalents on Unvested Awards. The Amended Plan prohibits the payment of dividends or dividend equivalents on unvested awards unless and until the awards vest.

Additional shares are necessary in order for us to meet our anticipated equity compensation needs

As of March 31, 2023, there were 400,541 shares remaining available for issuance under the 2019 Plan. If shareholders do not approve the Amended Plan, our ability to grant equity awards to our planned new hires, existing employees and other service providers will be limited, which we believe would place us at a competitive disadvantage in the extremely competitive labor market in which we operate.

In determining the number of shares that would be available under the Amended Plan, our Board considered the number of equity awards we granted during the past three fiscal years, as well our anticipated needs in the future. Our share burn rate over our three most recently completed fiscal years is shown below:


Fiscal Year	Number of Shares Subject to Options Granted		Number of Shares Subject to Full-Value Awards Granted		Total Shares Subject to Awards Granted		Weighted Average Common Shares Outstanding for the Fiscal Year Period		Burn Rate
2022		1,195,910		26,093		1,222,003		29,556,633		4.13	%
2021		1,326,675		0		1,326,675		27,616,839		4.80	%
2020		603,336		0		603,336		24,702,764		2.44	%
Average		1,041,974		8,698		1,050,671		27,292,079		3.79	%

After a review of our historical share usage practices and our anticipated future growth, we believe that the shares that would be available under the Amended Plan if this Proposal 3 is approved would enable us to continue to grant equity awards for approximately one to two years, from the date of this proxy statement. Having this additional number of shares available is vital to our ability to attract and retain talent.

Equity Plan Information as of March 31, 2023

The table below includes information regarding outstanding equity awards and shares available for futures awards under all currently active plans (the 2014 Stock Incentive Plan (“2014 Plan”), the 2019 Plan, and the Inducement Plan) as of March 31, 2023 (without giving effect to approval of the Amended Plan under this proposal).


Total shares available for future issuance under the 2014 Plan		0
Total shares available for future issuance under the 2019 Plan		400,541
Total shares available for future issuance under the Inducement Plan		504,984
Total shares underlying outstanding options under all plans		3,120,199
Weighted average exercise price of outstanding options under all plans	$	20.84
Weighted average remaining contractual life of outstanding options under all plans		8.04 years
Total shares subject to outstanding, unvested shares of time-based restricted stock under all plans		24,315
Total shares subject to outstanding, unvested time-based restricted stock units under all plans		182,911
Total shares subject to outstanding earned (performance condition satisfied) and unvested restricted stock and restricted stock unit awards under all plans		0
Total shares subject to outstanding unearned (performance condition not satisfied) restricted stock and restricted stock unit awards under all plans		0
Total common shares outstanding		32,534,003

-24-

Our current shares reserved for issuance in respect of outstanding awards plus our shares available for future awards (together, our “Total Overhang”) represents approximately 13.0% of our shares of common stock outstanding as of the record date. Should shareholders approve the Amended Plan, our resulting Total Overhang will represent approximately 16.4% of our shares of common stock outstanding (based on shares outstanding as of the record date). The Board believes our Total Overhang following adoption of the Amended Plan should not be viewed as excessive by shareholders based on typical total overhang levels of companies similar in size and industry to TransMedics.

SUMMARY OF THE AMENDED PLAN

The following is a brief summary of the material terms and features of the Amended Plan. A copy of the Amended Plan is attached as Appendix A to this Proxy Statement, and we urge our shareholders to read it in its entirety. The following description of certain terms and features of the Amended Plan is qualified in its entirety by reference to the full text of the Amended Plan.

Administration

The Amended Plan will generally be administered by our compensation committee, which will have the discretionary authority to administer and interpret the plan and any award granted under it; determine eligibility for and grant awards; determine the exercise price, base value or purchase price applicable to any awards; determine, modify and waive the terms and conditions of any award; determine the form of settlement of awards; prescribe forms, rules and procedures relating to the plan and awards; and otherwise do all things necessary or desirable to carry out the purposes of the plan or any award. Our compensation committee (or our board of directors, with respect to such matters over which it retains authority) may delegate to one or more of its members (or one or more members of our board of directors) such of its duties, powers and responsibilities as it may determine and, to the extent permitted by law, may delegate certain of its duties, powers and responsibilities to officers, employees and other persons. As used in this summary, the term “Administrator” refers to our compensation committee, our board of directors or any authorized delegates, as applicable.

Eligibility

Our and our subsidiaries’ key employees, directors, consultants and advisors will be eligible to participate in the Amended Plan. Eligibility for stock options intended to be incentive stock options (“ISOs”), will be limited to our employees and those of certain of our affiliates. Eligibility for stock options other than ISOs and stock appreciation rights (“SARs”), will be limited to individuals who are providing direct services on the date of grant of the award to us or certain of our affiliates. As of March 31, 2023, we estimate that approximately 226 employees and seven directors and 14 consultants or advisors would be eligible to participate in the Amended Plan.

Authorized Shares

Subject to adjustment as described below, the number of shares of our common stock that may be issued in satisfaction of awards under the Amended Plan will be 4,275,090 shares (consisting of 3,275,090 shares subject to outstanding awards or available for future issuance under the 2019 Plan as of March 31, 2023, plus 1,000,000 shares proposed to be available for issuance under the Amended Plan), plus the number of shares underlying awards under the 2014 Plan (not to exceed 516,452 shares) that on or after the date the Amended Plan was adopted by our Board of Directors expire or are terminated, surrendered or cancelled without the delivery of shares, are forfeited to or repurchased by us, or otherwise become available again for grant. The number of shares available for issuance under the Amended Plan is referred to in this summary as the “Share Pool.” A maximum of 4,275,090 shares from the Share Pool may be issued in satisfaction of ISOs. Shares withheld in payment of the exercise or purchase price of an award or in satisfaction of tax withholding requirements, and shares covered by a SAR any portion of which is settled in stock, will reduce the Share Pool. In addition, the Share Pool will not be

-25-

increased by any shares delivered under the 2019 Plan that are subsequently repurchased using proceeds directly attributable to stock option exercises. The Share Pool will not be reduced by any awards settled in cash or that expire, become unexercisable, terminate or are forfeited to or repurchased by us without the issuance of stock. Shares issued in substitution for equity awards of an acquired company that are converted, replaced or adjusted in connection with the acquisition will not reduce the Share Pool.

Shares that may be issued under our 2019 Plan may be authorized but unissued shares or shares acquired in an open-market transaction.

As of March 31, 2023, the closing price of our common stock was $75.73 per share.

Director Limits

The aggregate value of all compensation granted or paid to any non-employee director with respect to any calendar year, including awards under the Amended Plan, for his or her services as a director during such calendar year may not exceed $750,000 (or $1,000,000 for the year in which the director is first elected or appointed to our board of directors). The Administrator may make exceptions to such limits in extraordinary circumstances, as the Administrator may determine in its discretion, provided that the director to whom such exception applies may not participate in the decision to award compensation in excess of such limits.

Types of Awards

The Amended Plan provides for the grant of stock options, SARs, restricted and unrestricted stock and stock units, performance awards, and other awards that are convertible into or otherwise based on our common stock. Dividend equivalents may also be provided in connection with awards under the Amended Plan.

•

Stock Options and SARs. The Administrator may grant stock options, including ISOs, and SARs. A stock option is a right entitling the holder to acquire shares of our common stock upon payment of the applicable exercise price. A SAR is a right entitling the holder upon exercise to receive an amount (payable in cash or shares of equivalent value) equal to the excess of the fair market value of the shares subject to the right over the base value from which appreciation is measured. The per share exercise price of each stock option, and the per share base value of each SAR, granted under the Amended Plan may not be less than 100% of the closing price of a share of our common stock on the date of grant (or, if no closing price is reported for that date, on the immediately preceding date on which a closing price was reported) (110% in the case of certain ISOs).

•

Restricted and Unrestricted Stock and Stock Units. The Administrator may grant awards of stock, stock units, restricted stock and restricted stock units. A stock unit is an unfunded and unsecured promise, denominated in shares, to deliver shares or cash measured by the value of shares in the future, and a restricted stock unit is a stock unit that is subject to the satisfaction of specified performance or other vesting conditions. Restricted stock is stock subject to restrictions requiring that it be forfeited, redelivered or offered for sale to us if specified performance or other vesting conditions are not satisfied.

•

Performance Awards. The Administrator may grant performance awards, which are awards subject to performance vesting conditions, including the performance criteria described below.

•

Other Stock-Based Awards. The Administrator may grant other awards that are convertible into or otherwise based on shares of our common stock, subject to such terms and conditions as are determined by the Administrator.

•

Substitute Awards. The Administrator may grant substitute awards, which may have terms and conditions that are inconsistent with the terms and conditions of the Amended Plan.

-26-

Vesting; Terms and Conditions of Awards

The Administrator will determine the terms and conditions of all awards granted under the Amended Plan, including the time or times an award vests or becomes exercisable, the terms and conditions on which an option or SAR remains exercisable, and the effect of termination of a participant’s employment or service on awards. The Administrator may at any time accelerate the vesting or exercisability of an award.

Transfer Restrictions

Except as the Administrator may otherwise determine, awards may not be transferred other than by will or by the laws of descent and distribution.

Performance Criteria

The Amended Plan provides for grants of performance awards subject to “performance criteria.” Performance criteria may be applied to a participant individually, to a business unit or division of ours or to us as a whole and may relate to any or any combination of the following or any other criterion or criteria determined by the Administrator (measured either absolutely or comparatively (including, without limitation, by reference to an index or indices or the performance of one or more companies) and determined either on a consolidated basis or, as the context permits, on a divisional, subsidiary, line of business, project or geographical basis or in combinations thereof and subject to such adjustments, if any, as the Administrator specifies): sales; revenues; assets; expenses; earnings before or after deduction for all or any portion of interest, taxes, depreciation, or amortization, whether or not on a continuing operations or an aggregate or per share basis; return on equity, investment, capital or assets; one or more operating ratios; borrowing levels, leverage ratios or credit rating; market share; capital expenditures; cash flow; stock price; shareholder return; sales of particular products or services; customer acquisition or retention; acquisitions and divestitures (in whole or in part); joint ventures and strategic alliances; spin-offs, split-ups and the like; reorganizations; recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings; or strategic business criteria, consisting of one or more objectives based on: meeting specified market penetration or value added, product development or introduction (including, without limitation, any clinical trial accomplishments, regulatory or other filings or approvals, or other product development milestones), geographic business expansion, cost targets, cost reductions or savings, customer satisfaction, operating efficiency, acquisition or retention, employee satisfaction, information technology, corporate development (including, without limitation, licenses, innovation, research or establishment of third-party collaborations), manufacturing or process development, legal compliance or risk reduction, or patent application or issuance goals. Performance criteria may also be based on individual performance and/or subjective performance criteria not listed above and may be adjusted in a manner to reflect events occurring during the performance period that affect the performance criteria.

Effect of Certain Transactions

In the event of certain covered transactions (including a consolidation, merger or similar transaction, a sale of substantially all of our assets or common stock, a change in control, or a dissolution or liquidation of our company, the Administrator may, with respect to outstanding awards, provide for (in each case, on such terms and conditions as it determines):

•

The assumption, continuation or substitution for some or all awards (or any portion thereof) by the acquirer or surviving entity;

•

The acceleration of exercisability or issuance of shares in respect of any award (or any portion thereof), in full or in part; and/or

•

A cash payment in respect of some or all awards (or any portion thereof) equal to the difference between the fair market value of the shares subject to the award and its exercise or base price, if any.

-27-

Except as the Administrator may otherwise determine, each award will automatically terminate immediately upon the consummation of the covered transaction, other than awards that are substituted for, assumed or continued or awards that by their terms continue following the covered transaction.

Adjustment Provisions

In the event of a stock dividend, stock split or combination of shares (including a reverse stock split), recapitalization or other change in our capital structure, the Administrator will make appropriate adjustments to the maximum number of shares that may be issued under the Amended Plan, the individual limits described above, the number and kind of securities subject to, and, if applicable, the exercise or purchase prices (or base values) of, outstanding awards, and any other provisions affected by such event. The Administrator may also make such adjustments to take into account other distributions to shareholders or any other event if it determines that adjustments are appropriate to avoid distortion in the operation of the Amended Plan or any award.

Clawback

The Administrator may provide that any outstanding award or the proceeds from, or other amounts received in respect of, any award or stock acquired under any award will be subject to forfeiture and disgorgement to us, with interest and related earnings, if the participant to whom the award was granted is not in compliance with the plan or the applicable award or any non-competition, non-solicitation, no-hire, non-disparagement, confidentiality, invention assignment or other restrictive covenant. Each award will be subject to any of our policies or those of our subsidiaries that provides for the forfeiture, disgorgement or clawback with respect to incentive compensation that includes awards under the plan and will be subject to forfeiture and disgorgement to the extent required by law or applicable stock exchange listing standards.

Amendment and Termination

The Administrator may at any time amend the Amended Plan or any outstanding award and may at any time terminate the Amended Plan as to future grants. However, except as expressly provided in the Amended Plan or the applicable award, the Administrator may not alter the terms of an award so as to materially and adversely affect a participant’s rights without the participant’s consent, unless the Administrator expressly reserved the right to do so at the time the award was granted. Any amendments to the Amended Plan will be conditioned on shareholder approval to the extent required by law or applicable stock exchange requirements. No awards under the Amended Plan may be made after June 1, 2033, but previously granted awards may continue beyond that date in accordance with their terms.

CERTAIN FEDERAL INCOME TAX CONSEQUENCES OF THE AMENDED PLAN

This following is a summary of certain U.S. federal income tax consequences associated with awards granted under the Amended Plan. The summary does not purport to cover federal employment tax or other U.S. federal tax consequences that may be associated with the Amended Plan, nor does it cover state, local or non-U.S. taxes.

Stock Options (other than ISOs)

In general, a participant has no taxable income upon the grant of a stock option that is not intended to be an ISO (an “NSO”) but realizes income in connection with the exercise of the NSO in an amount equal to the excess (at the time of exercise) of the fair market value of the shares acquired upon exercise over the exercise price. A corresponding deduction is generally available to the Company, subject to the limitations set forth in the Code. Upon a subsequent sale or exchange of the shares, any recognized gain or loss is treated as a capital gain or loss for which the Company is not entitled to a deduction.

-28-

ISOs

In general, a participant realizes no taxable income upon the grant or exercise of an ISO. However, the exercise of an ISO may result in an alternative minimum tax liability to the participant. With some exceptions, a disposition of shares purchased pursuant to an ISO within two years from the date of grant or within one year after exercise produces ordinary income to the participant (and generally a deduction to the Company, subject to the limitations set forth in the Code) equal to the value of the shares at the time of exercise less the exercise price. Any additional gain recognized in the disposition is treated as a capital gain for which the Company is not entitled to a deduction. If the participant does not dispose of the shares until after the expiration of these one and two-year holding periods, any gain or loss recognized upon a subsequent sale of shares purchased pursuant to an ISO is treated as a long-term capital gain or loss for which the Company is not entitled to a deduction.

SARs

The grant of a SAR does not itself result in taxable income, nor does taxable income result merely because a SAR becomes exercisable. In general, a participant who exercises a SAR for shares of stock or receives payment in cancellation of a SAR will have ordinary income equal to the amount of any cash and the fair market value of any stock received. A corresponding deduction is generally available to the Company, subject to the limitations set forth in the Code.

Unrestricted Stock Awards

A participant who purchases or is awarded unrestricted stock generally has ordinary income equal to the excess of the fair market value of the shares at that time over the purchase price, if any, and a corresponding deduction is generally available to the Company, subject to the limitations set forth in the Code.

Restricted Stock Awards

A participant who is awarded or purchases shares subject to a substantial risk of forfeiture generally does not have income until the risk of forfeiture lapses. When the risk of forfeiture lapses, the participant has ordinary income equal to the excess of the fair market value of the shares at that time over the purchase price, if any, and a corresponding deduction is generally available to the Company, subject to the limitations set forth in the Code. However, a participant may make an election under Section 83(b) of the Code to be taxed on restricted stock when it is acquired rather than later, when the substantial risk of forfeiture lapses. A participant who makes an effective 83(b) election will realize ordinary income equal to the fair market value of the shares as of the time of acquisition less any price paid for the shares. A corresponding deduction will generally be available to the Company, subject to the limitations set forth in the Code. If a participant makes an effective 83(b) election, no additional income results by reason of the lapsing of the restrictions.

For purposes of determining capital gain or loss on a sale of shares awarded under the Amended Plan, the holding period in the shares begins when the participant recognizes taxable income with respect to the transfer. The participant’s tax basis in the shares equals the amount paid for the shares plus any income realized with respect to the transfer. However, if a participant makes an effective 83(b) election and later forfeits the shares, the tax loss realized as a result of the forfeiture is limited to the excess of what the participant paid for the shares (if anything) over the amount (if any) realized in connection with the forfeiture.

Restricted Stock Units

The grant of a restricted stock unit does not itself generally result in taxable income. Instead, the participant is taxed upon vesting (and a corresponding deduction is generally available to the Company, subject to the limitations set forth in the Code), unless he or she has made a proper election to defer receipt of the shares (or cash if the award is cash settled) under Section 409A of the Code. If the shares delivered are restricted for tax purposes, the participant will instead be subject to the rules described above for restricted stock.

-29-

NEW PLAN BENEFITS

No awards under the Amended Plan have been granted to date. Because future awards under the Amended Plan will be granted in the discretion of the Administrator, the type, number, recipients, and other terms of such awards cannot be determined at this time. The following table sets forth the awards that were granted to our named executive officers, our executive officers as a group, our non-employee directors as a group, and our other employees (who are not executive officers) as a group under the 2019 Plan for the fiscal year ended December 31, 2022.


Name and Position	Number of Shares Subject to Options
Waleed Hassanein, M.D., President and Chief Executive Officer		250,000
Stephen Gordon, Chief Financial Officer		52,000
Tamer Khayal, M.D., Chief Commercial Officer		52,000
Miriam Provost, Ph.D., Vice President of Global Regulatory Affairs		38,000
Laura Damme, Vice President, Clinical Affairs		38,000
Executive Officer Group		430,000
Non-Employee Director Group		94,500
Non-Executive Officer Employee Group		292,410

Required Vote and Recommendation of the Board of Directors

Approval of the proposal requires a majority of the votes cast by holders of shares of common stock who are present by remote communication or by proxy at a meeting at which a quorum is present is required to approve this proposal.

Our Board recommends that you vote FOR the proposal to approve the amendment to the TransMedics Group, Inc. 2019 Stock Incentive Plan in Proposal 3.

-30-

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table and accompanying footnotes set forth information with respect to the beneficial ownership of our common stock by:

•

each person known by us to beneficially own more than 5% of our common stock;

•

each of our named executive officers;

•

each of our directors (including the director nominees); and

•

all of our directors and executive officers as a group, based upon 32,534,003 shares of common stock outstanding as of March 31, 2023.

Beneficial ownership is determined under the SEC rules and regulations and generally includes voting or investment power over securities. Except in cases where community property laws apply or as indicated in the footnotes to this table, we believe each shareholder identified in the table possesses sole voting and investment power over all shares of equity securities shown as beneficially owned by the shareholder.

Shares of common stock subject to options that are currently exercisable or exercisable within 60 days of the date of March 31, 2023 are considered outstanding and beneficially owned by the person holding the options for the purposes of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as otherwise indicated, the address of each beneficial owner listed below is c/o TransMedics Group, Inc. 200 Minuteman Road, Suite 302, Andover, MA 01810.


Name of Beneficial Owner	Number of Shares Beneficially Owned		Percentage of Shares Beneficially Owned
5% or greater shareholders:
FMR LLC (1)		3,276,682		10.1	%
BlackRock, Inc. (2)		2,310,705		7.1	%
Macquarie Group Limited (3)		1,947,418		6.0	%
The Vanguard Group (4)		1,691,425		5.2	%
Directors and Named Executive Officers:
Waleed Hassanein, M.D. (5)		1,223,270		3.7	%
James Tobin (6)		273,025		*
Edward M. Basile (7)		63,033		*
Thomas Gunderson (8)		48,719		*
Edwin M. Kania, Jr. (9)		316,393		1.0	%
Stephanie Lovell (10)		4,039		*
Merilee Raines (11)		15,727		*
David Weill, M.D. (12)		33,500		*
Stephen Gordon (13)		68,943		*
Tamer Khayal, M.D. (14)		123,913		*
Miriam Provost, Ph.D. (15)		55,434		*
Laura Damme (16)		44,606		*
All executive officers and directors as a group (13 persons) (17)		2,270,602		6.7	%

*	Less than one percent.

(1)	Based on information filed with the SEC in a Schedule 13G/A on February 9, 2023. FMR LLC has sole voting power with respect to 3,275,545 shares and sole dispositive power with respect to 3,276,682 shares. FMR LLC’s address is 245 Summer Street, Boston, MA 02210.

-31-

(2)	Based on information filed with the SEC in a Schedule 13G/A on February 3, 2023. BlackRock, Inc. has sole voting power with respect to 2,272,295 shares and sole dispositive power with respect to 2,310,705 shares. BlackRock, Inc.’s address is 55 East 52nd Street, New York, NY 10055.

(3)

Based on information filed with the SEC in a Schedule 13G/A on February 14, 2023. According to the Schedule 13G/A, Macquarie Investment Management Business Trust has sole voting and dispositive power with respect to 1,947,418 shares. Macquarie Management Holdings Inc. is deemed to beneficially own 1,947,418 shares due to its ownership of Macquarie Investment Management Business Trust. Macquarie Group Limited is deemed to beneficially own 1,947,418 shares due to its ownership of Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust. The principal business address of Macquarie Group Limited is 50 Martin Place Sydney, New South Wales, Australia. The principal business address of Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust is 2005 Market Street, Philadelphia, PA 19103.

(4)

Based on information filed with the SEC in a Schedule 13G on February 9, 2023. The Vanguard Group has shared voting power with respect to 52,387 shares, sole dispositive power with respect to 1,612,860 shares and shared dispositive power with respect to 78,565 shares. The Vanguard Group’s principal business address is 100 Vanguard Blvd., Malvern, PA 19355.

(5)	Consists of (i) 536,859 shares held and (ii) 686,411 shares of common stock underlying outstanding stock options exercisable within 60 days of March 31, 2023.

(6)	Consists of (i) 243,591 shares of our common stock held by a revocable trust for which Mr. Tobin is the grantor and (ii) 29,434 shares of common stock underlying outstanding stock options exercisable within 60 days of March 31, 2023.

(7)	Consists of (i) 14,314 shares held and (ii) 48,719 shares of common stock underlying outstanding stock options exercisable within 60 days of March 31, 2023.

(8)	Consists of 48,719 shares of common stock underlying outstanding stock options exercisable within 60 days of March 31, 2023.

(9)	Consists of (i) 302,893 shares held, including 46,142 shares held by the Kania 2021 GRAT B, a grantor retained annuity trust, and (ii) 13,500 shares of common stock underlying outstanding stock options exercisable within 60 days of March 31, 2023.

(10)	Consists of 4,039 shares of common stock underlying outstanding stock options exercisable within 60 days of March 31, 2023.

(11)	Consists of 15,727 shares of common stock underlying outstanding stock options exercisable within 60 days of March 31, 2023.

(12)	Consists of (i) 10,000 shares held and (ii) 23,500 shares of common stock underlying outstanding stock options exercisable within 60 days of March 31, 2023.

(13)	Consists of (i) 5,714 shares held and (ii) 63,229 shares of common stock underlying outstanding stock options exercisable within 60 days of March 31, 2023.

(14)	Consists of (i) 32,127 shares held, including 19,776 shares held by the Khayal Family 2021 Irrevocable Trust and 11,051 shares held by the Tamer Ibrahim Ahmed Khayal Trust and (ii) 91,786 shares of common stock underlying outstanding stock options exercisable within 60 days of March 31, 2023.

(15)	Consists of (i) 15,154 shares held and (ii) 40,280 shares of common stock underlying outstanding stock options exercisable within 60 days of March 31, 2023.

(16)	Consists of (i) 44,606 shares of common stock underlying outstanding stock options exercisable within 60 days of March 31, 2023.

(17)	Consists of (i) 1,160,652 shares held and (ii) 1,109,950 shares of common stock underlying outstanding stock options exercisable within 60 days of March 31, 2023.

-32-

EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

This Compensation Discussion & Analysis (“CD&A”) explains our executive compensation program for our named executive officers listed below. This CD&A also describes our Compensation Committee’s process for making pay decisions, as well as its rationale for specific pay decisions related to the fiscal year ended December 31, 2022.


Name		Principal Position
Waleed Hassanein, M.D.		President and Chief Executive Officer
Stephen Gordon		Chief Financial Officer
Tamer Khayal, M.D.		Chief Commercial Officer
Miriam Provost, Ph.D.		Vice President of Global Regulatory Affairs
Laura Damme		Vice President, Clinical Affairs

EXECUTIVE SUMMARY

We are a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. Our Organ Care System (“OCS”) is a portable organ perfusion, optimization and monitoring system that utilizes our proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. The OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment. The OCS is the first and only multi-organ, portable platform that has received Premarket Approval (“PMA”) from the FDA.

Responsiveness to 2022 Say-on-Pay and Shareholder Feedback

As of January 1, 2022, we were no longer an “emerging growth company,” as defined in the JOBS Act of 2012. As such, our shareholders had their first opportunity to cast a non-binding advisory vote to approve our executive compensation (a “say-on-pay vote”) at our annual meeting in June 2022. The result of our first say-on-pay vote yielded approximately 42% support for our executive compensation program. Our Compensation Committee values feedback from our shareholders and has been highly focused on better understanding the concerns and perspectives of our shareholders that led to the low levels of support for the 2022 say-on-pay vote.

As a newly public company, we regularly meet with our shareholders to discuss business topics, seek feedback on our performance, and address other matters, such as executive compensation. We reached out to and engaged with shareholders throughout the year, including a broad outreach prior to our 2022 annual meeting and a more targeted outreach in the fall and winter of 2022 following our 2022 annual meeting. In total, we reached out to shareholders representing 62% of our common shares outstanding and met directly with shareholders representing 49% of our common shares outstanding. All shareholder meetings were attended by a member of the compensation committee and members of senior management. The Compensation Committee Chair participated in 91% of those meetings.

Through these exchanges, we gained greater appreciation for our shareholders’ views on compensation philosophies, annual and long-term incentive designs, performance metrics and governance. We reviewed the feedback with senior management, our Compensation Committee, and the entire Board. As part of this process, our Compensation Committee also retained Pearl Meyer, a leading independent compensation consulting firm, to gain further insight on current pay practices to ensure that our approach going forward effectively balances competitive market practices, shareholder expectations, best-practice governance standards and our business strategy.

-33-

What We Heard and What We Did

The outcome of our extensive outreach over the course of 2022 was to develop and begin executing on an aggressive, yet thoughtful, implementation timeline to respond to our shareholders’ priorities relating to our executive compensation program. To this end, our Compensation Committee made the following changes to our executive compensation program that more closely align with market best practices and shareholder feedback:


What We Heard		What We Did
Shareholders expect a compensation peer group that aligns with TransMedics’ valuation and growth trajectory		• Made substantive changes to the peer group for purposes of setting compensation levels for 2023: • Removed 15 companies due to valuation, current or forecasted revenue that were inconsistent with ours, or due to acquisition • Added 11 companies, which our Compensation Committee determined are industry appropriate and result in a group that, on balance, is more reflective of our size and growth trajectory

Shareholders would like clearer parameters around annual incentives, with maintained focus on achieving revenue targets		Beginning with 2023: • Goals will continue to focus on achievement of revenue targets and attainment of clearly defined strategic goals • Implemented a formulaic measurement of the revenue component of the bonus program • Implemented a payout cap of 200% of target for annual incentive payouts • Implemented a threshold performance level that requires us to achieve at least 80% of our revenue target and 3 of 5 of our most important strategic goals This newly adopted approach was developed throughout 2022 and therefore was not in place at the beginning of the year. However, the Compensation Committee applied the principles and philosophy embedded in 2023 program when making decisions about 2022 annual incentive award payouts.

Shareholders would like to see a more market-aligned, less-dilutive/cost-effective approach to equity-based compensation		Beginning with 2023: • Changed the equity mix for long-term incentives to incorporate full value awards: • Reduced weighting of stock options from 100% to 50% of the target total grant date fair value of equity-based compensation • Added restricted stock units (“RSUs”) with a weight of 50% of the target total grant date fair value of equity-based compensation • Worked with Pearl Meyer to analyze our peer group’s equity granting practices and found most companies phase in performance-based equity after first incorporating time-based full value awards; we are committed to evolving our equity mix over time to align with market best-practices for our industry and support our business and leadership talent retention objectives

Shareholders would like executives and non-employee directors to be subject to stock ownership requirements		• Implemented new stock ownership guidelines of 2x base salary for all C-level executives, 1x base salary for other executives, and 2x annual cash retainers for all non-employee directors

-34-


What We Heard		What We Did

Shareholders sought more clarity in our executive compensation program disclosure		• Provided enhanced transparency about our program in this CD&A, including more details around our executive compensation philosophy, overall executive compensation program structure, incentive plan goals and results, and our good governance practices

As our business and executive compensation program evolve, we will continue our shareholder engagement efforts and facilitate open and ongoing dialogues to help ensure that we have a regular pulse on investor perspectives. In the future, we will also continue to consider the feedback we receive from our shareholders as well as the outcome of say-on-pay votes when making compensation decisions regarding our executives.

2023 Target Compensation At-A-Glance (Pay Mix)

In support of the changes described above, the structure of our 2023 executive compensation program is closely aligned with Company performance and sensitive to the Company’s stock performance. The charts below show that a significant portion of named executive officer target total compensation (consisting of base salary, target annual bonuses and equity-based compensation, based on target total grant date fair value) is variable and “at-risk” (90% of the CEO’s 2023 target total compensation is performance-based with a significant portion (80%) tied to the future stock performance of the Company, and 78% of the other named executive officers’ 2023 target total compensation is performance-based with a significant portion (69%) tied to the future stock performance of the Company).

LOGO

-35-

Best Compensation Practices & Policies

We believe the following practices and policies within our executive compensation program promote sound governance principles and are in the best interests of our shareholders:


	What We Do		What We Don’t Do
✓	Emphasize variable pay over fixed pay, with a significant portion tied to our financial results and stock performance	✗	No change in control excise or other tax gross ups for any executives
✓	Maintain anti-hedging policies	✗	No repricing of underwater stock options or SAR without shareholder approval
✓	Maintain stock ownership guidelines	✗	No “single-trigger” change in control payments or benefits
✓	Use an independent compensation consultant	✗	No supplemental executive retirement plans
✓	Hold an annual say-on-pay vote	✗	No significant perquisites
✓	Conduct an annual compensation risk assessment	✗	No guaranteed bonuses or base salary increases

Business Overview and 2022 Performance Highlights

2022 was a transformative year for the Company, positioning us strongly for further growth. In summary, we experienced exceptional revenue growth and significantly grew commercial sales in the U.S. market. Our revenue grew by 209%, delivering more than three times the revenue of the prior year, which was driven by the FDA approval of our OCS Heart and OCS Liver devices at the end of 2021, along with the expansion and execution of our National OCS Program (“NOP”) to deliver end-to-end organ procurement and organ management services to our transplant center customers. In fact, approximately 90% of our U.S. revenue during 2022 was from customers utilizing the NOP across all three organ categories, allowing us to far outperform our goals. We also grew our manufacturing capacity to increase production, while maintaining the high quality required of class 3 medical devices.

In addition, we made very good progress on our longer-term projects, including the next generation OCS platform and our post-market data registries. We also solidified our balance sheet by refinancing our existing debt with a new, larger loan with a lower cost of capital and completed a follow-on equity financing — allowing us to continue our commercial expansion during 2022.

Our stock price since our May 2, 2019 initial public offering has outperformed both comparable market indices and our peer group, as shown below:

LOGO

-36-

We believe that the efforts of our named executive officers were critical to our success in 2022 and have positioned us well for growth in 2023 as we expand our National OCS Program to drive clinical adoption across all three transplant markets and capitalize on our unparalleled technology.

WHAT GUIDES OUR PROGRAM

Executive Compensation Philosophy & Objectives

To accomplish our business and growth objectives, we must be able to attract and retain talented executives whose skills and experience enable them to contribute to our long-term success. To that end, the philosophy and principal objectives of our executive compensation programs are to attract, fairly compensate, appropriately incentivize, and retain superior executive talent in a manner that aligns their long-term interests with those of our shareholders. Our executive compensation program is designed to be:

•

Responsibly Governed: Decisions about compensation should be guided by best-practice governance standards and rigorous processes that encourage prudent decision-making.

Elements of Pay: Total Direct Compensation

To support our philosophy and achieve our objectives, our Compensation Committee analyzes each of the following elements of compensation against comparative market data, and generally seeks to position each element around the market median, while differentiating individual compensation based on experience, role, position, individual performance, and other factors.


Pay Element	How It’s Paid	Purpose
Base Salary	Cash (Fixed)	Provide a competitive base salary rate relative to similar positions in the market and enable us to attract and retain critical executive talent.

Annual Bonuses	Cash (Variable)	Tie a significant portion of our executives’ cash compensation opportunities to the attainment of performance goals that we believe will help us attain short- and long-term business objectives

Equity-Based Compensation	Equity (Variable)	Provide incentives for executives to execute on longer-term financial goals that drive the creation of shareholder value and also support our leadership retention objectives.

The Decision-Making Process

Compensation Committee

Our Compensation Committee oversees our executive compensation program and administers our cash and equity incentive plans. Our Compensation Committee reviews and approves the compensation of our Chief

-37-

Executive Officer and other executives, including the type and amount of each element of compensation and the performance goals applicable to incentive compensation. As described below, our Compensation Committee also works with members of management and obtains advice from an independent compensation consultant in the course of making its compensation decisions.

The Role of Management

Our Chief Executive Officer, Chief Financial Officer, and Vice President of Human Resources, working with internal resources as well as with our Compensation Committee’s compensation consultant, review our executive compensation program on an annual basis and make recommendations as to the type and amount of compensation based on its review of peer group and other market data, individual performance and other factors. Our Chief Executive Officer makes recommendations to our Compensation Committee regarding the compensation of our executives other than himself based on these same factors. Our Chief Executive Officer, Chief Financial Officer, and Vice President of Human Resources typically attend meetings of our Compensation Committee but do not participate in any discussions regarding their own compensation.

Independent Compensation Consultant

Through August 2022, our Compensation Committee continued its engagement with Radford, to serve as its independent compensation consultant and provide it with advice on a broad range of executive and non-employee director compensation-related matters, including the development of a peer group for compensation setting purposes and assistance in determining competitive levels of compensation for our executives and non-employee directors. In September 2022, after an extensive review process by the Board, our Compensation Committee retained the services of Pearl Meyer as its independent compensation consultant for the remainder of the year. Pearl Meyer was engaged to support our Compensation Committee’s efforts to conduct a comprehensive analysis of the current executive compensation program in response to shareholder feedback. Our Compensation Committee has determined, based on its analysis and in light of all relevant factors, that the work of Radford and Pearl Meyer has not created any conflicts of interest, and that Radford and Pearl Meyer are independent pursuant to the independence standards set forth in the Nasdaq listing standards promulgated pursuant to Section 10C of the Exchange Act.

Use of Peer Group and Market Data

2022 Compensation Peer Group. Our Compensation Committee uses peer group and other market data as a reference point to gauge the reasonableness of our executive compensation decisions and the general competitiveness of our executive compensation program in the market and to assist it in determining the type and amount of compensation that we pay. For purposes of setting compensation levels for 2022, our Compensation Committee, working in consultation with Radford, selected companies operating in the healthcare equipment/medical device industry or the early commercial bio/pharma and diagnostic industry with a comparable market capitalization (targeting companies with a market value of between 0.3x and 3.0x our market value), revenue (targeting companies with revenues between 0.5x and 2.5x our current/projected revenue) and headcount (targeting companies with a number of employees between 0.3x and 3.0x our current/projected headcount). Our Compensation Committee also qualitatively evaluated each prospective peer group company based on business focus and corporate strategy to identify companies in a similar space, to the extent possible (e.g., devices for transplant, organs), and seeks to maintain year-over-year continuity in our peer group by maintaining flexibility in applying the foregoing criteria, particularly in uncertain market conditions. The compensation peer group companies selected by our Compensation Committee for 2022 executive compensation purposes are listed below.


2022 Peer Group
Acutus Medical, Inc.	BioLife Solutions, Inc.	Cytosorbents Corporation	Eargo, Inc.
Intersect ENT, Inc.	IRadimed Corporation	Neuronetics, Inc.	Ocular Therapeutix, Inc.
OrthoPediatrics, Corp.	Outset Medical, Inc.	Pulmonx Corporation	Pulse Biosciences, Inc.
Semler Scientific, Inc.	Senseonics Holdings, Inc.	SI-BONE, Inc.	Sientra, Inc.
Silk Road Medical, Inc.	Surmodics, Inc.	Treace Medical Concepts, Inc.	Vapotherm, Inc.
View Ray, Inc.

-38-

2023 Compensation Peer Group. Ensuring that our compensation peer group is aligned with our business objectives is an ongoing priority — especially as we evolve at a rapid pace. In September 2022, our Compensation Committee’s new independent consultant, Pearl Meyer, conducted a comprehensive analysis to ensure that the compensation peer group is aligned with our valuation and growth trajectory. The 2023 Compensation Peer Group was constructed using similar quantitative and qualitative criteria used for the 2022 Compensation Peer Group. Upon review of the 2022 Compensation Peer Group and in consultation with Pearl Meyer, our Compensation Committee determined that many of our 2022 peers were no longer comparable to TransMedics due to the significant growth we experienced in 2022. As such, our Compensation Committee approved Pearl Meyer’s recommendation to change the compensation peer group for purposes of setting executive compensation levels for 2023 as follows:


	Additions (+11 Companies): On balance, these companies are more reflective of the size, scope and growth trajectory of TransMedics (market capitalization and revenue levels)		Removals (-15 Companies): Removed due to valuation or current or forecasted revenue that is inconsistent with ours, or, in the case of Intersect ENT, Inc., because it was acquired
✓	AtriCure, Inc.	✗	Acutus Medical, Inc.
✓	Axonics, Inc.	✗	Cytosorbents Corporation
✓	Butterfly Network, Inc.	✗	Eargo, Inc.
✓	CareDx, Inc.	✗	Intersect ENT, Inc.
✓	Establishment Labs Holdings Inc.	✗	IRadimed Corporation
✓	Glaukos Corporation	✗	Neuronetics, Inc.
✓	Nevro Corp.	✗	Ocular Therapeutix, Inc.
✓	PROCEPT BioRobotics Corporation	✗	Pulse Biosciences, Inc.
✓	SomaLogic, Inc.	✗	Semler Scientific, Inc.
✓	STAAR Surgical Company	✗	Senseonics Holdings, Inc.
✓	Twist BioScience Corporation	✗	SI-BONE, Inc.
		✗	Sientra, Inc.
		✗	Surmodics, Inc.
		✗	Vapotherm, Inc.
		✗	View Ray, Inc.


2023 Peer Group
AtriCure, Inc.	Axonics, Inc.	BioLife Solutions, Inc.	Butterfly Network, Inc.
CareDx, Inc.	Establishment Labs Holdings Inc.	Glaukos Corporation	Nevro Corp.
OrthoPediatrics, Corp.	Outset Medical, Inc.	PROCEPT BioRobotics Corporation	Pulmonx Corporation
Silk Road Medical, Inc.	SomaLogic, Inc	STAAR Surgical Company	Treace Medical Concepts, Inc.
Twist BioScience Corporation

2022 EXECUTIVE COMPENSATION PROGRAM IN DETAIL

Base Salary

Each of our named executive officers is paid a base salary. Our Compensation Committee believes this element of compensation is important because it provides a fixed element of compensation that reflects the individual named executive officer’s skills, experience and role. Base salaries are established based on peer group data and other market data, as described above, and each named executive officer’s skill set, experience, role and responsibilities, are reviewed annually and may be adjusted based on such factors. In 2021, we did not increase the base salaries of our executive officers as a result of uncertainties related to the global COVID-19 pandemic. For 2022, our Compensation Committee reviewed the base salaries for our named executive officers and, taking

-39-

into account the factors described above approved increases to the annual base salaries of the named executive officers for 2022 as shown in the table below:


Named Executive Officer	2021 Annual Base Salary		2022 Annual Base Salary		% Increase
Waleed Hassanein, M.D.	$	535,000	$	590,000		10.3	%
Stephen Gordon	$	370,800	$	435,000		17.3	%
Tamer Khayal, M.D.	$	386,250	$	435,000		12.6	%
Miriam Provost, Ph.D.	$	329,600	$	340,000		3.2	%
Laura Damme	$	262,500	$	320,000		21.9	%

Increases for all named executive officers other than Dr. Provost reflect our Compensation Committee’s attempt to bring base salaries closer to the applicable market 50^th percentile, determined as described above. Dr. Provost was provided with a merit adjustment as her base salary was found to be competitive with market.

Annual Bonuses

Our Compensation Committee believes that a significant portion of our named executive officers’ cash compensation should be tied to our performance. Each of our named executive officers is eligible to receive an annual bonus based on the achievement of certain financial and strategic performance goals related to revenue growth, and regulatory and business goals. Target annual bonus opportunities are reviewed annually by our Compensation Committee based on the same factors as described above for base salary. For 2022, our Compensation Committee reviewed the target annual bonus opportunities for our named executive officers and, taking into account the factors described above, decided not to make any changes to the targets, except to increase Ms. Damme’s target by 5% to 35% based on analysis of industry market data. The 2022 target annual bonus opportunities for our named executive officers were as follows:


Named Executive Officer	2022 Target Cash Bonus Opportunity
Waleed Hassanein, M.D.		90	%
Stephen Gordon		45	%
Tamer Khayal, M.D.		45	%
Miriam Provost, Ph.D.		35	%
Laura Damme		35	%

2022 Performance Goals

Our Compensation Committee determines the performance metrics and goals for our annual bonus program in the beginning of each year based on input from management and our annual business plan. Our Compensation Committee strives to set challenging, yet achievable, performance goals that will promote the achievement of short-term business objectives that are important to our annual business plan. The performance metrics for annual bonuses include financial and non-financial strategic goals that reflect our growth strategy and purpose. In 2022, our Compensation Committee determined bonus payouts based on a formulaic measurement of revenue performance against budget and additionally considered our achievement of non-financial strategic goals when reviewing performance. Our Compensation Committee may also consider individual performance contributions and retains the discretion to adjust bonus payouts downward or upward based on its assessment of each named executive officer’s contribution to the Company during the year.

-40-

The specific metrics and goals that were approved by our Compensation Committee for 2022, as well as the actual achievement results, are outlined below:


2022 Performance Metrics and Goals		Results
Revenue target of $55M		$92.1M
Financing the business: raise $50M or more		Achieved
Receive FDA approval of DCD Heart indication		Achieved
Expand NOP to include all three organs in United States		Achieved
Maintain supply of high-quality OCS products		Achieved
Complete development of OCS Hardware program to mitigate obsolescence		Achieved
Meet FDA enrollment milestones for post-approval registries for heart & liver		Achieved

In addition to the performance goals set forth above, our Compensation Committee initially set a performance goal related to our OCS Heart pre-clinical follow-up study, which was subsequently removed from our 2022 annual bonus program as our business goals relating to this product changed to anticipate a 2023 completion date.

By applying the principles and philosophy embedded in 2023 program when making decisions about 2022 annual incentive award payouts and based on our 2022 revenue of $92.1 million (167% of our target revenue of $55 million, and which amount excludes $1.4 million of clinical trial related contra revenue recognized in 2022) and achievement of all of our non-financial strategic objectives, our Compensation Committee determined that each named executive officer would receive a bonus of 167% of target for 2022. Our Compensation Committee did not apply any further discretion to the calculated payout. Resulting bonus payouts for our named executive officers are for 2022 are set forth below:


Named Executive Officer	2022 Annual Base Salary		2022 Target Annual Bonus Opportunity (as a % of Salary)			2022 Target Annual Bonus Opportunity		2022 Actual Annual Bonus Payout (as a % of Target)			Actual Annual Bonus Payout
Waleed Hassanein, M.D.	$	590,000		90	%	$	531,000		167	%	$	886,770
Stephen Gordon	$	435,000		45	%	$	195,750		167	%	$	326,903
Tamer Khayal, M.D.	$	435,000		45	%	$	195,750		167	%	$	326,903
Miriam Provost, Ph.D.	$	340,000		35	%	$	119,000		167	%	$	198,730
Laura Damme	$	320,000		35	%	$	112,000		167	%	$	187,040

Equity Incentive Awards

Our Compensation Committee believes that in order to appropriately incentivize our named executive officers to create shareholder value, a significant portion of our named executive officers’ compensation should be in the form of equity-based compensation. Our equity-based compensation program is designed to promote stock ownership by our executives and senior management, tie compensation realized to stock price performance and encourage retention.

Historically, and based on the equity-based compensation practices at companies of a similar size and stage of development as TransMedics in recent years, our approach to granting equity-based compensation to executives has been in the form of stock options. Stock options are intended to align the interests of award recipients with those of shareholders since stock options only deliver value if our stock price appreciates after they are granted.

In 2022, our named executive officers were again granted stock options that vest on a monthly basis over four years, generally subject to the named executive officer’s continued employment with us. Our Compensation

-41-

Committee determined the number of shares subject to each named executive officer’s option based on competitive market data, as described above, and by analyzing total executive ownership levels, retention from previously granted stock options and other factors.

We recognize that as we continue to mature as a business, our approach to granting equity awards using 100% stock options awards is more representative of private companies. As such, and as described in the Executive Summary section of this CD&A, we are evolving our compensation practices with our business strategy, and our Compensation Committee is committed to putting forth a program that aligns the interests of our executives and shareholders. Specifically, effective January 1, 2023, we changed the equity mix for long-term incentives to incorporate full value awards by:

•

Reducing weight of stock options from 100% to 50% of the target total grant date fair value of equity-based compensation; and

•

Adding RSUs with a weight of 50% of the target total grant date fair value of equity-based compensation.

We also worked with Pearl Meyer to analyze our peers’ equity granting practices and found most companies phase in performance-based equity after first incorporating time-based full value shares. We are committed to evolving our equity mix over time to align with market best-practices for our industry and support our business and leadership talent retention objectives.

OTHER COMPENSATION PRACTICES, POLICIES & GUIDELINES

Stock Ownership Guidelines

The Board believes that our most senior executives (including our named executive officers) should hold meaningful equity ownership positions in the Company, in part to align our executives’ interests with those of our shareholders. Effective January 1, 2023, the Board adopted guidelines requiring each C-level executive to hold shares equal to two (2) times base salary.

Executives will have five (5) years from the date of implementation of the stock ownership guidelines to attain the ownership threshold. Holdings that satisfy this stock ownership requirement include shares owned outright and unvested RSUs. Stock options and unearned performance-based awards do not count towards satisfying the ownership requirement.

Compliance with stock ownership guidelines will be evaluated annually. All of our C-level executives are on track to be in compliance with the stock ownership guidelines.

Clawback Policy

We expect to adopt a clawback policy regarding accounting restatements in accordance with the SEC’s adoption of new rules to implement Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 once such final rule is implemented by Nasdaq.

Employee Benefits

We maintain a tax-qualified retirement plan that provides all of our full-time U.S. employees, including our named executive officers, with an opportunity to save for retirement on a tax-advantaged basis. Under our 401(k) plan, participants may elect to defer a portion of their compensation on a pre-tax basis and have it contributed to the plan, subject to applicable annual limits under the Internal Revenue Code of 1986, as amended. We did not make any employer contributions to our 401(k) plan for the fiscal year ended December 31, 2022. Our named executive officers participate in our 401(k) plan on the same basis as other eligible employees. We do not maintain any qualified or non-qualified defined benefit plans or supplemental executive retirement plans that cover our named executive officers.

-42-

All of our full-time employees, including our named executive officers, are eligible to participate in our health and welfare plans, including medical, dental, vision, life and accidental death and dismemberment benefits and short-term and long-term disability insurance. Our named executive officers participate in these plans on the same basis as other eligible employees. We do not maintain any supplemental health or welfare plans for our named executive officers.

Change in Control and Severance Benefits

We have entered into offer letters with Mr. Gordon, Dr. Khayal, Dr. Provost and Ms. Damme that set forth the initial terms and conditions of employment, and we have entered into retention agreements with Dr. Hassanein, Mr. Gordon and Dr. Khayal that provide for severance payments and benefits in connection with certain terminations of employment. Dr. Provost’s offer letter provides for severance payments in connection with certain terminations of employment. In addition, certain of the equity awards granted to our named executive officers would vest in connection with a qualifying termination of employment following a change in control. These severance payments and benefits are more fully described below under “Potential Payments upon Termination or Change in Control.” Our Compensation Committee believes that reasonable severance payments and benefits are necessary to attract and retain executives and are important in incentivizing them to pursue a change in control transaction if it is in the best interests of our shareholders even if it creates uncertainty for them.

Anti-Hedging Policy

Our insider trading policy prohibits our directors, officers and employees from entering into hedging or monetization transactions, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds, because such transactions may permit a director, officer or employee to continue to own securities obtained through our employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the individual may no longer have the same objectives as our other shareholders.

Compensation Risk Assessment

Our Compensation Committee regularly reviews our compensation policies and practices, including the risks created by our compensation plans, and has concluded that any risks arising from our compensation policies and practices are not reasonably likely to have a material adverse effect on the Company.

Tax and Accounting Considerations

Our Compensation Committee considers the tax and accounting consequences of compensation paid under our executive compensation program. However, our Compensation Committee believes that its primary responsibility is to maintain an executive compensation program that attracts, retains and rewards our executives. Accordingly, our Compensation Committee has paid, and may continue to pay, in its discretion, compensation that is not fully deductible or is limited as to tax deductibility.

COMPENSATION COMMITTEE REPORT

Our Compensation Committee has reviewed and discussed the “Compensation Discussion and Analysis” disclosure with management. Based on this review and discussion, our Compensation Committee recommended to our Board that the “Compensation Discussion and Analysis” be included in the Proxy Statement distributed in connection with the Annual Meeting.

The Compensation Committee:

James R. Tobin (Chair)

Thomas J. Gunderson

Merilee Raines

David Weill, M.D.

-43-

This report shall not be deemed soliciting material or to be filed with the SEC, or incorporated by reference in any document so filed, whether made before or after the date hereof, except to the extent we specifically request that it be treated as soliciting material or it is specifically incorporated by reference therein.

Summary Compensation Table

The following table sets forth the compensation awarded to, earned by, or paid to our named executive officers during our fiscal years ended December 31, 2022, December 31, 2021 and, if applicable, December 31, 2020.


Name and Principal Position	Year		Salary ($) (1)		Bonus ($) (2)		Option Awards ($) (3)		Non-Equity Incentive Plan Compensation ($) (4)		Total($)
Waleed Hassanein, M.D.		2022		575,192		—		1,825,900		886,770		3,287,862
President and Chief Executive Officer		2021		535,000		—		6,377,940		457,425		7,370,365
President and Chief Executive Officer		2020		533,627		406,100		1,445,960		—		2,385,687
Stephen Gordon		2022		417,715		—		379,787		326,903		1,124,405
Chief Financial Officer		2021		370,800		—		1,440,180		158,517		1,969,497
Chief Financial Officer		2020		370,510		141,831		405,485		—		917,826
Tamer Khayal, M.D.		2022		421,875		—		379,787		326,903		1,128,565
Chief Commercial Officer		2021		386,250		—		1,440,180		165,122		1,991,552
Chief Commercial Officer		2020		385,947		147,741		405,485		—		939,173
Miriam Provost, Ph.D. (5)		2022		337,200		—		277,537		198,730		813,467
Vice President of Global Regulatory Affairs		2021		329,600		—		514,350		109,592		953,542
Laura Damme (6)		2022		304,519		—		277,537		187,040		769,096
Vice President, Clinical Affairs		2021		262,500		—		514,350		74,813		851,663

(1)	The amounts reported in this column include contributions made by the named executive officer to our 401(k) plan, which is described below.

(2)	The amounts reported in this column represent the annual bonuses paid for the fiscal year ended December 31, 2020.

(3)

The amounts reported in this column represent the aggregate grant date fair value of options to purchase our common stock granted during the fiscal years ended December 31, 2022, December 31, 2021 and December 31, 2020, as applicable, computed in accordance with FASB ASC 718, excluding the effect of estimated forfeitures. These amounts do not represent the actual amounts paid to or realized by the named executive officer for these awards. The assumptions used to value the options for this purpose are set forth in Note 10 to our financial statements filed with our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, Note 10 to our financial statements filed with our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and Note 10 to our financial statements filed with our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

(4)	Amounts represent annual bonuses paid for the fiscal year ended December 31, 2022 and December 31, 2021. See “Compensation Discussion and Analysis — Annual Cash Incentive Bonuses” above for additional details.

(5)	Pursuant to SEC rules, no amounts are included for Dr. Provost or Ms. Damme for 2020 because they were not named executive officers in such year.

-44-

Grants of Plan-Based Awards Table

The following table sets forth information regarding plan-based awards made to each of our named executive officers during 2022.


	Grant Date		Estimated Future Payouts Under Non-Equity Incentive Plan Awards (1)						All Other Option Awards: Number Of Securities Underlying Options (#) (2)		Exercise or Base Price of Option Awards ($/Sh) (3)		Grant Date Fair Value of Stock and Option Awards ($) (4)
Name	Grant Date		Threshold ($)		Target ($)		Maximum ($)				Exercise or Base Price of Option Awards ($/Sh) (3)		Grant Date Fair Value of Stock and Option Awards ($) (4)
Waleed Hassanein		—		—		531,000		—		—				—
		2/22/2022		—		—		—		250,000		13.28		1,825,900
Stephen Gordon		—		—		195,750		—		—				—
		2/22/2022		—		—		—		52,000		13.28		379,787
Tamer Khayal		—		—		195,750		—		—				—
		2/22/2022		—		—		—		52,000		13.28		379,787
Miriam Provost		—		—		119,000		—		—				—
		2/22/2022		—		—		—		38,000		13.28		277,537
Laura Damme		—		—		112,000		—		—				—
		2/22/2022		—		—		—		38,000		13.28		277,537

(1)

Amounts represent the target annual cash bonus opportunities by our named executive officers under our annual bonus program. There were no set thresholds or maximums under our annual bonus program for 2022. See “Compensation Discussion and Analysis — Annual Bonuses” above for additional details. The actual amounts paid to our named executive officers under our annual bonus program for 2022 are set forth in the Non-Equity Incentive Plan Compensation of the Summary Compensation Table above.

(2)	Amounts represent the number of shares of our common stock subject to stock options granted to our named executive officers in 2022. See “Compensation Discussion and Analysis — Equity Incentive Awards” above for additional details.

(3)	Amounts represent the exercise price for the stock options granted to our named executive officers in 2022.

(4)

These amounts represent the grant date fair value of stock options granted in 2022, determined in accordance with FASB ASC Topic 718, disregarding the effect of forfeitures. These amounts do not represent the actual amounts paid to or realized by the named executive officer for these awards during 2022. For a more detailed description of the assumptions used for purposes of determining grant date fair value see Note 10 to the consolidated financial statements set forth in our Annual Report on Form 10-K for the year ended December 31, 2022.

-45-

Outstanding Equity Awards at 2022 Year-End

The following table shows the number of vested and unvested equity awards held by our named executive officers as of December 31, 2022.


Named Executive Officer	Number of Securities Underlying Unexercised Options (#) Exercisable (1)		Number of Securities Underlying Unexercised Options (#) Unexercisable		Option Exercise Price ($)		Option Expiration Date
Waleed Hassanein		193,074		—		2.21		6/21/2027
		261,904		23,810		16.00		4/30/2029
		126,083		51,917		16.14		2/27/2030
		142,083		167,917		38.46		2/24/2031
		52,083		197,917		13.28		2/22/2032
Stephen Gordon		16,144		14,584		16.14		2/27/2030
		32,083		37,917		38.46		2/24/2031
		10,833		41,167		13.28		2/22/2032
Tamer Khayal		58,927		5,358		16.00		4/30/2029
		35,416		14,584		16.14		2/27/2030
		32,083		37,917		38.46		2/24/2031
		10,833		41,167		13.28		2/22/2032
Miriam Provost		18,281		—		3.22		4/4/2028
		3,851		4,375		16.14		2/27/2030
		1,563		13,542		38.46		2/24/2031
		7,916		30,084		13.28		2/22/2032
Laura Damme		15,000		3,000		21.89		8/5/2029
		10,625		4,375		16.14		2/27/2030
		521		13,542		38.46		2/24/2031
		7,916		30,084		13.28		2/22/2032

(1)	The shares underlying the options vest on a monthly basis over a four-year period from the grant date, which is ten years prior to the applicable expiration date listed in the table above, generally subject to continued service through each such vesting date.

Option Exercises and Stock Vested

The following table shows the stock options that our named executive officers exercised during 2022. No stock awards held by any of our named executive officers vested during 2022.


	Option Awards
Name	Number of Shares Acquired on Exercise (#)		Value Realized on Exercise ($) (1)
Waleed Hassanein		122,371		2,214,915
Stephen Gordon		60,000		2,548,841
Tamer Khayal		68,059		3,152,904
Miriam Provost		13,644		390,248
Laura Damme		10,937		239,637

(1)	The amounts reported in this column is based on the per share closing price of a share of our common stock on the Nasdaq Stock Market on the date the applicable stock options were exercised.

-46-

Pension Benefits and Nonqualified Deferred Compensation

None of our named executive officers participated in or received benefits from a pension plan or from a nonqualified deferred compensation plan during 2022 or in any prior year.

Potential Payments Upon Termination or Change in Control

We have entered into offer letters with Mr. Gordon, Dr. Khayal, Dr. Provost and Ms. Damme that set forth the initial terms and conditions of the executive’s employment with us. We have also entered into a retention agreement with Dr. Hassanein, Mr. Gordon and Dr. Khayal that provides for severance payments and benefits in the event the named executive officer’s employment is terminated in certain circumstances. Dr. Provost’s offer letter provides for severance payments in connection with certain terminations of employment, and Ms. Damme is not contractually entitled to receive severance payments or benefits in connection with a termination of employment. In addition, each of our named executive officers has entered into an invention and non-disclosure disclosure agreement and a non-competition and non-solicitation agreement with us. The material terms of these agreements are summarized below. As used in the summary below, the terms “cause,” “disability,” “good reason” and “change in control” have the meanings set forth in the applicable agreement.

Dr. Hassanein. Pursuant to his retention agreement, Dr. Hassanein is entitled to severance payments and benefits in the event we terminate his employment other than for cause or due to his death or disability or if Dr. Hassanein resigns for good reason. If his employment terminates in such circumstances, Dr. Hassanein will be entitled to receive (i) an amount equal to the sum of his highest annual base salary during the preceding three years and his highest annual bonus during the preceding three years, payable in 12 monthly installments; (ii) Company-provided benefits for up to 12 months; (iii) an additional 12 months of service credit for purposes of eligibility for any retiree benefits; and (iv) any accrued but unpaid compensation and benefits, including a prorated annual bonus for the year in which his employment terminates, based on Dr. Hassanein’s annual bonus for the preceding year, subject, in each case, to his execution of a release of claims and compliance with the material provisions of any employment, consulting, advisory, nondisclosure, non-competition or similar agreement with us. If his employment terminates in such circumstances either in connection with or in anticipation of, or within 24 months following, a change in control, then, in lieu of the payments and benefits described above, Dr. Hassanein will be entitled to receive (A) an amount equal to one and one-half (1.5) times the sum of his highest annual base salary during the preceding three years and his highest annual bonus during the preceding three years, payable in a lump sum; (B) Company-provided benefits for up to 18 months; (C) an additional 18 months of service credit for purposes of eligibility for any retiree benefits; (D) accelerated vesting of all of his then-outstanding and unvested stock options, restricted stock, and other equity-based awards; and (E) any accrued but unpaid compensation and benefits, including a prorated annual bonus for the year in which his employment terminates, based on Dr. Hassanein’s annual bonus for the preceding year.

Dr. Khayal. Pursuant to his retention agreement, Dr. Khayal is entitled to severance payments and benefits in the event we terminate his employment other than for cause or due to his death or disability or if Dr. Khayal resigns for good reason. If his employment terminates in such circumstances, Dr. Khayal will be entitled to receive (i) an amount equal to three-fourths (.75) times the sum of his highest annual base salary during the preceding three years and his highest annual bonus during the preceding three years, payable in nine monthly installments; (ii) Company-provided benefits for up to nine months; (iii) an additional nine months of service credit for purposes of eligibility for any retiree benefits; and (iv) any accrued but unpaid compensation and benefits, including a prorated annual bonus for the year in which his employment terminates, based on Dr. Khayal’s annual bonus for the preceding year, subject, in each case, to his execution of a release of claims and compliance with the material provisions of any employment, consulting, advisory, nondisclosure, non-competition or similar agreement with us. If his employment terminates in such circumstances either in connection with or in anticipation of, or within 24 months following, a change in control, then, in lieu of the payments and benefits described above, Dr. Khayal will be entitled to receive (A) an amount equal to the sum of his highest annual base salary during the preceding three years and his highest annual bonus during the preceding three years, payable in

-47-

a lump sum; (B) Company-provided benefits for up to 12 months; (C) an additional 12 months of service credit for purposes of eligibility for any retiree benefits; (D) accelerated vesting of all of his then-outstanding and unvested stock options, restricted stock, and other equity-based awards; and (E) any accrued but unpaid compensation and benefits, including a prorated annual bonus for the year in which his employment terminates, based on Dr. Khayal’s annual bonus for the preceding year.

Mr. Gordon. Pursuant to his retention agreement, Mr. Gordon is entitled to severance payments and benefits in the event we terminate his employment other than for cause or due to his death or disability or if Mr. Gordon resigns for good reason. If his employment terminates in such circumstances, Mr. Gordon will be entitled to receive (i) an amount equal to three-fourths (.75) times the sum of his highest annual base salary during the preceding three years and his highest annual bonus during the preceding three years, payable in nine monthly installments; (ii) Company-provided group health insurance benefits for up to nine months; and (iii) any accrued but unpaid compensation and benefits, including a prorated annual bonus for the year in which his employment terminates, based on Mr. Gordon’s annual bonus for the preceding year, subject, in each case, to his execution of a release of claims and compliance with the material provisions of any employment, consulting, advisory, nondisclosure, non-competition or similar agreement with us. If his employment terminates in such circumstances either in connection with or in anticipation of, or within 24 months following, a change in control, then, in lieu of the payments and benefits described above, Mr. Gordon will be entitled to receive (A) an amount equal to the sum of his highest annual base salary during the preceding three years and his highest annual bonus during the preceding three years, payable in a lump sum; (B) Company-provided group health insurance benefits for up to 12 months; (C) accelerated vesting of all of his then-outstanding and unvested stock options, restricted stock, and other equity-based awards; and (D) any accrued but unpaid compensation and benefits, including a prorated annual bonus for the year in which his employment terminates, based on Mr. Gordon’s annual bonus for the preceding year.

Dr. Provost. Pursuant to her offer letter, Dr. Provost is entitled to severance payments in the event we terminate her employment other than for cause. If her employment terminates in such circumstances, Dr. Provost will be entitled to receive an amount equal to six months’ base salary. Dr. Provost’s offer letter does not provide for enhanced severance payments and benefits in connection with or in anticipation of, or within a period of time following, a change in control.

Ms. Damme. Ms. Damme has not entered into a retention agreement, and does not otherwise have a contractual entitlement to receive severance payments and benefits upon a termination of her employment for any reason.

Restrictive Covenants. Each of our named executive officers has entered into an invention assignment and non-disclosure agreement and a non-competition and non-solicitation agreement with us that contain covenants relating to the disclosure of proprietary and confidential information and the assignment of inventions, and non-competition, no-hire and employee and customer non-solicitation covenants that apply for one year following the termination of the named executive officer’s employment with us.

Each of Dr. Hassanein, Mr. Gordon, and Dr. Khayal is entitled to severance payments and benefits under his retention agreement upon a termination of employment in certain circumstances, including in connection with a change in control. Dr. Provost is entitled to severance payments under her offer letter upon a termination of employment in certain circumstances. These severance payments and benefits are described above.

280G Better Of Provision. Each of the retention agreements described above provides that we will not be obligated to provide any payments or benefits to the named executive officer that would constitute “excess parachute payments’’ within the meaning of Section 280G of the Code, unless such payments and benefits would result in a greater after-tax amount to the named executive officer than if the payments and benefits were reduced so that no amount was subject to the excise tax imposed with respect to such payments (to the extent applicable).

The table below sets forth the change in control and severance benefits that would be payable to our named executive officers if his or her employment terminated under the circumstances described below, in each case, on

-48-

December 31, 2022. No benefits would be payable upon a change in control without an associated termination of employment.


Name	Benefit Continuation ($) (1)		Severance ($) (2)		Acceleration of Unvested Options ($) (3)		Total
Waleed Hassanein
Voluntary Termination/Retirement		—		—		—		—
Termination prior to Change in Control without Cause or for Good Reason		41,712		1,476,770		—		1,518,482
Termination following Change in Control without Cause or for Good Reason		62,568		2,215,155		16,947,819		19,225,542
Resignation without Good Reason following Change in Control; Termination for Death or Disability		—		—		—		—
Termination for Cause; Resignation without Good Reason		—		—		—		—
Stephen Gordon
Voluntary Termination/Retirement		—		—		—		—
Termination prior to Change in Control without Cause or for Good Reason		31,284		571,427		—		602,711
Termination following Change in Control without Cause or for Good Reason		41,712		761,903		3,540,818		4,344,433
Resignation without Good Reason following Change in Control; Termination for Death or Disability		—		—		—		—
Termination for Cause; Resignation without Good Reason		—		—		—		—
Tamer Khayal
Voluntary Termination/Retirement		—		—		—		—
Termination prior to Change in Control without Cause or for Good Reason		31,160		571,427		—		602,587
Termination following Change in Control without Cause or for Good Reason		45,536		761,903		3,785,785		4,593,224
Resignation without Good Reason following Change in Control; Termination for Death or Disability		—		—		—		—
Termination for Cause; Resignation without Good Reason		—		—		—		—
Miriam Provost
Voluntary Termination/Retirement		—		—		—		—
Termination prior to Change in Control without Cause or for Good Reason		—		170,000		—		170,000
Termination following Change in Control without Cause or for Good Reason		—		—		—		—
Resignation without Good Reason following Change in Control; Termination for Death or Disability		—		—		—		—
Termination for Cause; Resignation without Good Reason		—		—		—		—
Laura Damme
Voluntary Termination/Retirement		—		—		—		—
Termination prior to Change in Control without Cause or for Good Reason		—		—		—		—
Termination following Change in Control without Cause or for Good Reason		—		—		—		—
Resignation without Good Reason following Change in Control; Termination for Death or Disability		—		—		—		—
Termination for Cause; Resignation without Good Reason		—		—		—		—

-49-

(1)	Benefit continuation amounts are calculated based on the cost of premiums under our group health plans as of December 31, 2022.

(2)

Severance amounts are the amounts payable under the applicable named executive officer’s retention agreement or, in the case of Dr. Provost, her offer letter. Ms. Damme has not entered into a retention agreement, and does not otherwise have a contractual entitlement to receive severance payments and benefits upon a termination of her employment for any reason.

(3)

Acceleration of Unvested Options amounts reflect the value of stock options that would accelerate upon a termination of employment by the Company without cause or a resignation by our named executive officers for good reason in connection with or in anticipation of, or within 24 months following, a change in control. Values for equity-based awards have been determined using the closing price of a share of our common stock on December 31, 2022 ($61.72).

CEO Pay Ratio

Under SEC rules, we are required to disclose the ratio of our CEO’s annual total compensation to the median of the annual total compensation of all of our other employees. We determined that the 2022 median of the annual total compensation of all of our employees who were employed as of December 31, 2022, other than our CEO, Dr. Hassanein, was $134,896. Dr. Hassanein’s 2022 annual total compensation was $3,287,862 (as reported in our Summary Compensation Table above). Based on the foregoing, our estimate of the ratio of Dr. Hassanein’s annual total compensation to the median annual total compensation of all of our other employees was 24 to 1.

To identify the median employee, we used Box 5 W-2 data for all individuals employed by us on December 31, 2022, annualizing such data for those individuals employed by us for less than the full year of 2022. Dr. Hassanein was excluded from this exercise.

As of December 31, 2022, our total population, excluding Dr. Hassanein, consisted of 211 employees located in the United States, France, Germany, Italy, and the United Arab Emirates. Pursuant to SEC rules, we excluded 1 employee located in France, 2 employees located in Germany, 2 employees located in Italy, and 1 employee located in the United Arab Emirates (which were all of our employees in such jurisdictions) to identify our median employee. After applying this exemption, the employee population, excluding Dr. Hassanein, used for purposes of identifying the median employee consisted of 205 employees. We then calculated the annual compensation of the median employee using the same methodology used to calculate Dr. Hassanein’s compensation for the Summary Compensation Table.

We believe that the pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules based on our internal records and the methodology described above. The SEC rules for identifying the median employee and calculating the pay ratio based on that employee’s annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. Therefore, our ratio may not be comparable to the ratios disclosed by other companies based on a number of factors, including differences in employee populations, different geographic distributions of employees, and the nature of the companies’ businesses.

Pay Versus Performance Disclosure

In accordance with rules adopted by the SEC pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we provide the following disclosure regarding executive “Compensation Actually Paid” (“CAP”) and certain performance measures for the fiscal years listed below. The CD&A describes the compensation setting process for our executive officers, which is done independently from the disclosure requirements.

-50-

Pay Versus Performance

The following table provides the information required for our named executive officers for each of the fiscal years ended December 31, 2022, December 31, 2021, and December 31, 2020 along with the required financial information required for each fiscal year. CAP is calculated in accordance with SEC rules and includes the increase or decrease in value of certain elements of compensation over each fiscal year, including compensation granted in a prior year. CAP does not correlate to the total amount of cash or equity compensation paid or received during each fiscal year. The calculations do not reflect the actual sale of stock underlying equity awards or the exercise of stock options by the executive, and the amount of compensation ultimately received may, in fact, be different from the CAP amounts disclosed in the table below.


									Year-end value of $100 invested on December 31, 2019 in:
	Summary Compensation Table Total for PEO (1)		Compensation Actually Paid to PEO (2)(3)(4)		Average Summary Compensation Table Total for Non-PEO NEOs (5)		Average Compensation Actually Paid to Non-PEO NEOs (2)(3)(4)(5)		Total Shareholder Return		Peer Group Total Shareholder Return (6)		Net Income (in millions)		Revenue (in millions)
Year	$		$		$		$		$		$		$		$
2022		3,287,862		25,221,430		958,883		4,539,264		324.67		99.81		-36.2		93.5
2021		7,370,365		5,172,911		1,441,564		1,068,071		100.79		125.43		-44.2		30.3
2020		2,385,687		2,664,885		928,500		1,040,799		104.68		130.04		-28.7		25.6

(1)	For all years reported, the principal executive officer (“PEO”) was Waleeed Hassanein, M.D., President and Chief Executive Officer.

(2)	Deductions from, and additions to, total compensation in the Summary Compensation Table (“SCT”) by year to calculate CAP include:


	2022						2021						2020
	Waleed Hassanein, M.D. $			Average of Other Non-PEO NEOs $			Waleed Hassanein, M.D. $			Average of Other Non-PEO NEOs $			Waleed Hassanein, M.D. $			Average of Other Non-PEO NEOs $
Total Compensation from SCT		3,287,862			958,883			7,370,365			1,441,564			2,385,687			928,500
Total Adjustments for Pension		—			—			—			—			—			—
Adjustments for Equity Awards
Adjustment for SCT grant date fair value		(1,825,900	)		(328,662	)		(6,377,940	)		(977,265	)		(1,445,960	)		(405,485	)
Year-end fair value of unvested awards granted in the current year		10,641,343			1,915,465			2,075,640			318,044			1,671,240			469,456
Year-over-year difference of year-end fair values for unvested awards granted in prior years		8,789,191			1,344,193			(136,022	)		(16,872	)		67,300			9,331
Fair value at vesting date for awards granted and vested in current year		1,647,831			296,601			949,688			145,504			312,077			87,658
Difference in fair values between prior year-end fair values and vesting date fair values for awards granted in prior years		2,681,103			352,784			1,291,179			157,096			(325,459	)		(48,661	)
Forfeitures during current year equal to prior year-end fair value		—			—			—			—			—			—
Dividends or dividend equivalents not otherwise included in total compensation		—			—			—			—			—			—
Total Adjustments for Equity Awards		21,933,568			3,580,381			(2,197,454	)		(373,493	)		279,198			112,300
Compensation Actually Paid (as calculated)		25,221,430			4,539,264			5,172,911			1,068,071			2,664,885			1,040,799

-51-

Table of Contents

(3)	The following summarizes the valuation assumptions used for stock option awards included as part of CAP:

Expected life of each stock option is based on the “simplified method” using an average of the remaining vesting period and remaining term, as of the applicable vesting date or fiscal year end.

Strike price is based on each grant date closing price and asset price is based on the closing price on the applicable vesting date or fiscal year end.

Risk free rate is based on the Treasury Constant Maturity rate closest to the remaining expected life as of the applicable vesting date or fiscal year end.

Historical volatility is based on the daily price history for each year of remaining expected life prior to each applicable vesting date or fiscal year end; closing prices are provided by S&P Capital IQ and are adjusted for dividends and splits.

Represents annual dividend yield on each applicable vesting date or fiscal year end.

(4)	The folowing table illustrates the valuation assumptions as of the vesting date for awards that vested in each of 2022, 2021 and 2020:


	For Stock Options Vesting in
	2022	2021	2020
Expected volatility	69.15% - 76.30%	64.38% - 72.22%	56.71% - 71.56%
Expected dividend yield	0.00%	0.00%	0.00%
Expected term, in years	3.2 - 5.0	3.0 - 5.0	3.2 - 5.0
Risk-free interest rate	0.97% - 4.48%	0.19% - 1.34%	0.15% - 1.69%

(5)	Non-PEO named executive officers reflect the average SCT total compensation and average CAP for the following executives by year:

2022: Stephen Gordon (Chief Financial Officer), Tamer Khayal, M.D. (Chief Commercial Officer), Miriam Provost, Ph.D. (Vice President of Global Regulatory Affairs), and Laura Damme (Vice President, Clinical Affairs).

2021: Stephen Gordon (Chief Financial Officer), Tamer Khayal, M.D. (Chief Commercial Officer), Miriam Provost, Ph.D. (Vice President of Global Regulatory Affairs), and Laura Damme (Vice President, Clinical Affairs).

2020: Stephen Gordon (Chief Financial Officer) and Tamer Khayal, M.D. (Chief Commercial Officer).

(6)	For purposes of the “Peer group total shareholder return” column of this table, the Nasdaq Healthcare Index (IXHC) was used as our selected peer group.

Tabular List of Financial Performance Measures

As described in greater detail in the CD&A, we have a significant focus on

pay-for-performance.

The most important financial and

non-financial

performance measures used to link CAP (as calculated in accordance with the SEC rules), to our named executive officers in 2022 to our performance were:

•

Revenue;

•

Financing the business;

•

Receive FDA approval and/or meet enrollment milestones; and

•

Expand, maintain, and continue developing current high-quality programs and products.

-52-

Table of Contents

Narrative Disclosure: Pay Versus Performance Table

The graphs below provide a description of CAP (as calculated in accordance with the SEC rules) and the following measures:

•

TransMedics’ cumulative total shareholder return and Peer Group (Nasdaq Healthcare Index) cumulative total shareholder return;

•

TransMedics’ Net Income; and

•

the Company Selected Measure, which for TransMedics is Revenue.

-53-

Table of Contents

-54-

REPORT OF THE AUDIT COMMITTEE

The information contained in this report shall not be deemed to be “soliciting material” or “filed” or incorporated by reference in future filings with the SEC, or subject to the liabilities of Section 18 of the Exchange Act, except to the extent that the Company specifically incorporates it by reference into a document filed under the Securities Act or the Exchange Act.

We operate in accordance with a written charter adopted by our Board and reviewed annually by the audit committee. We are responsible for overseeing the quality and integrity of TransMedics Group, Inc.’s accounting, auditing and financial reporting practices and internal controls. In accordance with the rules of the SEC and Nasdaq, the audit committee is composed entirely of members who are independent, as defined by the listing standards of Nasdaq and TransMedics Group, Inc.’s Corporate Governance Guidelines. Further, our Board has determined that three of our members (Mr. Kania, Ms. Raines and Mr. Gunderson) are audit committee financial experts as defined by the rules of the SEC.

The audit committee met five times during fiscal 2022 with TransMedics Group, Inc.’s management and PricewaterhouseCoopers LLP (“PwC”), TransMedics Group, Inc.’s independent registered public accounting firm, including, but not limited to, meetings held to review and discuss the annual audited and quarterly financial statements and the Company’s earnings press releases.

We believe that we fully discharged our oversight responsibilities as described in our charter, including with respect to the audit process. We reviewed and discussed our audited financial statements for the fiscal year ended December 31, 2022, with management and PwC. Management has the responsibility for the preparation of TransMedics Group Inc.’s financial statements and the effectiveness of internal control over financial reporting and procedures that are reasonably designed to assure compliance with accounting standards and applicable laws and regulations, and PwC has the responsibility for the audit of the Company’s financial statements. The Audit Committee discussed with PricewaterhouseCoopers LLP the matters required to be discussed by Public Company Accounting Oversight Board (“PCAOB”) Auditing Standard No. 1301 and the SEC. We received the written disclosures and the letter from PwC pursuant to Rule 3526, Communication with Audit Committees Concerning Independence, of the PCAOB, concerning any relationships between PwC and TransMedics Group, Inc. and the potential effects of any disclosed relationships on PwC’s independence, and discussed with PwC its i

SEC Form DEF 14A filed by TransMedics Group Inc.